Theses and Dissertations                    1. Thesis and Dissertation Collection, all items

2016-12

# Determining the optimal inventory management policy for Naval Medical Center San Diego's Pharmacy

Galka, Jason S.

Monterey, California: Naval Postgraduate School

http://hdl.handle.net/10945/51698

# NAVAL
# POSTGRADUATE
# SCHOOL

**MONTEREY, CALIFORNIA**

# THESIS

### DETERMINING THE OPTIMAL INVENTORY MANAGEMENT POLICY FOR NAVAL MEDICAL CENTER SAN DIEGO'S PHARMACY

by

Jason S. Galka

December 2016

| | |
|---|---|
| Thesis Advisor: | Eddine Dahel |
| Second Reader: | Bryan Hudgens |

**Approved for public release. Distribution is unlimited.**

THIS PAGE INTENTIONALLY LEFT BLANK

| REPORT DOCUMENTATION PAGE | | *Form Approved OMB No. 0704–0188* |
|---|---|---|
| Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instruction, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188) Washington, DC 20503. | | |
| **1. AGENCY USE ONLY** *(Leave blank)* | **2. REPORT DATE** December 2016 | **3. REPORT TYPE AND DATES COVERED** Master's thesis |
| **4. TITLE AND SUBTITLE** DETERMINING THE OPTIMAL INVENTORY MANAGEMENT POLICY FOR NAVAL MEDICAL CENTER SAN DIEGO'S PHARMACY | | **5. FUNDING NUMBERS** |
| **6. AUTHOR(S)** Jason S. Galka | | |
| **7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)** Naval Postgraduate School Monterey, CA 93943-5000 | | **8. PERFORMING ORGANIZATION REPORT NUMBER** |
| **9. SPONSORING /MONITORING AGENCY NAME(S) AND ADDRESS(ES)** N/A | | **10. SPONSORING / MONITORING AGENCY REPORT NUMBER** |
| **11. SUPPLEMENTARY NOTES** The views expressed in this thesis are those of the author and do not reflect the official policy or position of the Department of Defense or the U.S. Government. IRB number ____N/A____. | | |
| **12a. DISTRIBUTION / AVAILABILITY STATEMENT** Approved for public release. Distribution is unlimited. | | **12b. DISTRIBUTION CODE** |

**13. ABSTRACT (maximum 200 words)**

Inventory management in Navy pharmacies uses outdated technologies and strategies and desperately needs updating. The management of inventory should never use a one-size-fits-all approach, and the optimal inventory management system was determined for Naval Medical Center San Diego (NMCSD). This thesis used demand data gathered from NMCSD to investigate the periodic review and continuous review systems with single item ordering and joint quantity ordering to determine which was best for NMCSD. The results of this study are that joint ordering with continuous review is less expensive than single item ordering and periodic review of inventory. It is recommended that NMCSD begin looking into the costs and how to begin implementing a continuous review system.

| **14. SUBJECT TERMS** pharmacy inventory management policies | | | **15. NUMBER OF PAGES** 63 |
|---|---|---|---|
| | | | **16. PRICE CODE** |
| **17. SECURITY CLASSIFICATION OF REPORT** Unclassified | **18. SECURITY CLASSIFICATION OF THIS PAGE** Unclassified | **19. SECURITY CLASSIFICATION OF ABSTRACT** Unclassified | **20. LIMITATION OF ABSTRACT** UU |

THIS PAGE INTENTIONALLY LEFT BLANK

# DETERMINING THE OPTIMAL INVENTORY MANAGEMENT POLICY FOR NAVAL MEDICAL CENTER SAN DIEGO'S PHARMACY

Jason S. Galka
Lieutenant Commander, United States Navy
PharmD, Albany College of Pharmacy, 2009

Submitted in partial fulfillment of the
requirements for the degree of

**MASTER OF BUSINESS ADMINISTRATION**

from the

**NAVAL POSTGRADUATE SCHOOL**
**December 2016**

Approved by:        Eddine Dahel, Ph.D.
                   Thesis Advisor


                   Bryan Hudgens
                   Second Reader


                   Bryan Hudgens
                   Academic Associate
                   Graduate School of Business and Public Policy

THIS PAGE INTENTIONALLY LEFT BLANK

# ABSTRACT

Inventory management in Navy pharmacies uses outdated technologies and strategies and desperately needs updating. The management of inventory should never use a one-size-fits-all approach, and the optimal inventory management system was determined for Naval Medical Center San Diego (NMCSD). This thesis used demand data gathered from NMCSD to investigate the periodic review and continuous review systems with single item ordering and joint quantity ordering to determine which was best for NMCSD. The results of this study are that joint ordering with continuous review is less expensive than single item ordering and periodic review of inventory. It is recommended that NMCSD begin looking into the costs and how to begin implementing a continuous review system.

THIS PAGE INTENTIONALLY LEFT BLANK

# TABLE OF CONTENTS

# LIST OF FIGURES

THIS PAGE INTENTIONALLY LEFT BLANK

# LIST OF TABLES

# LIST OF ACRONYMS AND ABBREVIATIONS

| | |
|---|---|
| BCF | Basic Core Formula |
| C | Unit Cost |
| CHCS | Composite Health Care System |
| D | Annual Demand |
| DOD | Department of Defense |
| DOS | Days of Stock |
| DUR | Drug Utilization Review |
| EOQ | Economic Order Quantity |
| GS | General Schedule |
| h | Holding cost |
| IEN | Internal Entry Number |
| $n*$ | Ideal number of reorders per year |
| MTF | Military Treatment Facility |
| NGO | Non-Governmental Organization |
| NMCSD | Naval Medical Center San Diego |
| P&T | Pharmacy and Therapeutics |
| PAR | Product Activity Report |
| RLS | Restless Leg Syndrome |
| ROP | Reorder Point |
| $S*$ | Combined Ordering Cost |
| $s$ | Common Order Cost |
| SKU | Stock Keeping Unit |
| SOP | Standard Operating Procedure |
| TMOP | Tricare Mail Order Pharmacy |
| VEN(D) | Vital, Essential, Non-Essential |

THIS PAGE INTENTIONALLY LEFT BLANK

# ACKNOWLEDGMENTS

THIS PAGE INTENTIONALLY LEFT BLANK

# I.    INTRODUCTION

Each year all of the services across the Department of Defense (DOD) spend billions of dollars filling prescriptions, using one of three options: Military Treatment Facility (MTF) pharmacies, Tricare Mail Order Pharmacy (TMOP), or retail pharmacies. For both the government and the Tricare beneficiary, the most expensive option is to fill a prescription using the retail network (Government Accountability Office [GAO], 2008). Through various incentive-based plans, the DOD is trying to shift demand from the retail networks to one of the two preferred methods of filling prescriptions, the MTF pharmacies or TMOP (GAO, 2008). With 9.6 million Tricare beneficiaries in 2012 (Congressional Budget Office [CBO], 2014), many of whom fill at least one prescription every year, this would result in millions of prescriptions to fill throughout the DOD.

With new demand being brought back to MTFs, combined with new technologies, it is necessary and more cost effective for the pharmacies to change how they maintain inventory. New research has made inventory management a science rather than conjecture. Countless different inventory management systems can be customized specifically to meet the customer's individual needs. Using computers, it is easy to gather and analyze data, and even have a computer decide when and how much of an item to order. There are over 80 pharmacies in the Navy system, each managing its own inventory of as many as 2,300 items or stock keeping units (SKU). Managing these items by hand is difficult, time-consuming, and not an efficient use of resources.

This thesis will examine the inventory management of one of the largest pharmacies in Navy Medicine, Naval Medical Center San Diego (NMCSD) Pharmacy. The focus will be on the management of the outpatient division and will not include the demand for inpatient medications. Using data generated from NMCSD, an inventory management system utilizing economic order quantities (EOQ) with joint ordering and random order generation will be evaluated and compared with periodic inventory management.

The NMCSD Pharmacy is responsible for filling an average of 2,500-2,800 prescriptions daily, about 1 million prescriptions each year, with over 2,300 unique stock keeping units (SKU) (research from NMCSD, July 22, 2016). It is surprising that a pharmacy this size still relies heavily on older outdated methods of managing its inventory. Reorders are initiated by visually inspecting each of the 2,300 SKU daily or may result if there is a prescription for a medication and there is none left on the shelf. There is no reliable electronic or other system that the pharmacy's staff can use to determine the actual on hand inventory of any items. If a pharmacist, technician or supply staff would like to know how much of an item is in stock presently, the best and only way to do this is to walk to the shelf and count what is there. This leaves a lot of room for error; there could be misplaced medications or several bottles off the shelf because they are being used, and there is no accountability to compare what is actually present with what should be present. However, NMCSD does use some technology to make their lives easier. When walking the shelves to re-order medications, NMCSD's supply staff use a barcode scanner to enter the quantity on the shelf, and automatically re-order the medication up to the pre-set quantity.

The NMCSD supply workflow is actually very simple. Each day three technicians spend about three hours walking the shelves reordering the medications as needed (Vancheri, 2016). The supply staff has quite a large quantity buffer because their goal day of stock (DOS) is 30 days' worth and place orders five days a week, Monday through Friday, and usually receive their orders the following day (Vancheri, 2016). There are exceptions when the prime vendor is out of stock or there is a manufacturer back order, but this occurs infrequently. When the order cannot be fulfilled by the next business day, the order is then cancelled and must be redone (Vancheri, 2016).

The supply staff has gained significant expertise through on-the-job training and the experience that comes with working a job a many years. If they were to turn over their duties to someone else, it almost certainly would take much longer than nine hours to accomplish; shortages or overstock would almost certainly occur until the new staff got accustomed to the job. While this study looks specifically at NMCSD, not all MTFs have the same resources. At smaller MTFs, there may not be a designated supply staff,

only someone who does it part-time or a military member who will turnover very quickly. A facility like this may use a lot of extra resources to keep their inventory at sufficient levels. The benefits of optimizing inventory management could be transferred to all Navy pharmacies and may even have a larger impact in other pharmacies that do not have the same kind of resources as NMCSD. The largest benefit may be to an overseas pharmacy, where the supply staff turnover is arguably the highest. With a process like inventory management that already has a high learning curve, practicing in an overseas setting has increased demands due to a longer lead-time with much more variability.

The purpose of this thesis is to analyze the demand at NMCSD and use that to determine an optimal inventory management system. The study will compare a continuous inventory management system with a periodic inventory system. The status quo at NMCSD is a hybrid of the periodic and the visual method of inventory management, a continuous review system would allow for a the technician to fill prescriptions rather than order medications, decreasing the patient's wait time or even allowing the technician to go home on time. The hope of the study is to demonstrate the benefits and detriments of each management system to allow NMCSD to make as educated a decision as possible.

THIS PAGE INTENTIONALLY LEFT BLANK

# II.    BACKGROUND AND LITERATURE REVIEW

## A.    BACKGROUND

Running a military outpatient pharmacy is very similar to managing a community pharmacy such as Walgreens or CVS. They both have patients in need of medication and customers expect that, in a short amount of time they can go home with medications in hand. The expectation of visiting a pharmacy is that the medication will be in stock and filled in a relatively short period of time. Due to the fact that medications play a significant roll in public health, consumers view a stock outage as an incredibly negative experience; stock outages can result in a loss of customers if it happens frequently. To prevent this, pharmacies must have a high service level on all of their items to prevent such stock outages. However, medications or inventory in pharmacies are the largest asset in pharmacy practice, as much as 75% of a pharmacy's costs can be associated with inventory (Bouldin, Holmes, & Garner, 2011). The cost of inventory is made even more difficult because there is such a growth in the number of drugs on the market as well as the number of people who need these medications (Ali, 2011). The corporate goal of a civilian community pharmacy is to make a profit; a large component of this is to minimize the opportunity cost of inventory by not tying up capital in unnecessary inventory. Military pharmacies are different because troop readiness and the overall health of beneficiaries, active duty, their dependents and retirees, are the goals of a military pharmacy, rather than profit. However, this does not mean that inventory management is not important.

## B.    LITERATURE REVIEW

This section will introduce different costs associated with pharmacy practice, specifically costs associated with managing inventory. Two different methods of inventory categorization will be explained and later used to decide which medications to focus the study on. Lastly, the different inventory management models that will be used in this study will be introduced.to focus inventory management models

### 1. Pharmacy Inventory Associated Costs

Acquisition, procurement, carrying, and shortage costs are the four major costs associated with maintaining inventory (Ali, 2011).

#### a. *Acquisition costs*

Four factors to determine the acquisition cost of medication inventory and are responsible for the growth in the value of a pharmacy's inventory: price, utilization, mix, and innovation (American Society for Health-System Pharmacists [ASHP], 2008).

##### (1) Price

Price is the cost of individual medications, and can be driven down with the use of generic medications, if available. This is important because medications, even older medications that have been on the market for a while are getting more expensive. Take the case of the EpiPen®. This is an auto-injectable form of epinephrine that is used to save lives when an anaphylactic allergic reaction occurs. Since 2010, the cost of this vital medication has increased to five times what it was, peaking at just over $600 per pack (Lipton & Abrams, 2016).

##### (2) Utilization

Utilization or demand is the number of people filling prescriptions or the demand of the medication. Nearly 60% of Americans take routine medications daily and this number has increased significantly since 2000 (Dennis, 2015). This increase in demand can be attributed to the rising number of Americans who take medications to treat conditions such as depression, hypertension, or diabetes (Dennis, 2015). In the last 12 years alone, the number of people taking more than five medications has risen from 8% to 15% (Dennis, 2015). With the demand for medications increasing so dramatically, pharmacies must maintain a higher amount of medications on their shelves, which increases the acquisition costs as well as holding costs.

(3)     Mix

Mix is when newer medications are developed that are typically better and more expensive than the medications in which they replace. This type of cost is usually associated with older medications coming off of patents and being replaced with "updated" versions, such as a long acting form or combination product like Caduet®. This medication was released by Pfizer combines the cholesterol-lowering drug Lipitor (atorvastatin) and the hypertension drug Norvasc (amlodipine) (Pfizer, 2016) making it essential for pharmacies to carry three different medications, Lipitor, Norvasc, and Caduet®, each with several dosages, rather than two.

(4)     Innovation

Innovation is the cost of medications to treat a condition that was previously untreatable (ASHP, 2008). Perhaps one of the most obvious examples of this was when Viagra® (Sildenafil) was first released to treat erectile dysfunction. Innovative costs are a combination of utilization and mix costs (ASHP, 2008).

All of these costs are tied into the acquisition cost of medications (Ali, 2011), which is essentially the total amount of money that is used on the medications themselves or the cost of the medications themselves. Assuming a proper quantity is ordered, much of the acquisition cost is unavoidable. A pharmacy will order and use what is demanded.

**b.     *Procurement Costs***

Procurement costs are the costs involved in purchasing medications such as managing or placing orders and stocking shelves once the medications arrive (Ali, 2011). These costs are mostly personnel costs and are a function of the time and salaries of the individuals who do these tasks. The best way to manage these costs is to remember time is money (Sloan, 2015). Becoming more efficient with ordering is one way to reduce procurement costs. It is also important to remember that spending a lot of time looking for the best price on a medication may actually increase the total price because saving a couple pennies on that medication may cost more in hours of time (Sloan, 2015).

### *c.* *Costs*

Carrying costs are costs incurred as a result of having the inventory; any loss, theft, or damage, as well as the cost of expiring medications fall into this category (Ali, 2011). The best way to reduce this cost is to minimize wastage and/or shrinkage

### *d.* *Shortage Costs*

Shortage cost is difficult to put a dollar value on. It can include making rush orders, or the cost of a lost customer, or even the physical health that may be impacted as a result of a stock outage (Ali, 2011). The military system is a little different in that customers are told where they can fill their prescriptions. MTF pharmacy customers are highly incentivized to use MTF pharmacies with 90-day supplies and zero co-pays, but they will still use a network pharmacy at a greater expense to the DOD.

### 2. **ABC Analysis/Pareto Principle**

An ABC analysis or the Pareto Principle can determine the best way to allocate resources and help plan inventory (American Society for Health-System Pharmacists, 2008). The Pareto Principle is a very old theory that states 20% of inputs result in 80% of the results (Lavinsky, 2014). In this case, the Pareto Principle implies that 20% of inventory items result in roughly 80% of budget. The ABC Analysis takes this principle and applies it slightly differently. While the Pareto Analysis divides items into two categories, 20% and 80%, the ABC analysis divides it into three: A, B, and C items (World Health Organization [WHO], 2012). There are some variations in how the categories are divided and often there is a natural or obvious divide. Typically the A items represent about 10–15% of the items or 70–80% of the total cost, B items approximately represent the next 20–25% of the inventory or 15–20% of the budget, and the remaining 60–70% of the items account for only 5–10% of the budget (Devani, Gupta, & Nigah, 2010). The ABC analysis can have a significant impact on identifying areas for improvement. Any cost reduction of the "A" items will have the most meaningful and immediate impact on inventory costs, while the "C" items will have a minimal and relatively insignificant impact on cost savings. For the purpose of this study, the ABC Analysis will be used to help decide which items to focus on to decide order

quantities and re-order points. By ordering smaller quantities more frequently, holding costs can be reduced, however this may lead to an increase in procurement costs from more frequent ordering and receiving. It may also be possible to reduce safety stock with more frequent orders. Not included in the scope of this study, important savings opportunities can be observed by focusing on finding lower cost sources of medications of "A" items as well as monitoring their expiration dates more closely to ensure proper stock rotation (WHO, 2012).

### 3.　　　Vital, Essential, Non-Essential Categorization

Another way to differentiate medications is to use the VEN system, sometimes called the VED system or simply the VN system. With this system the "V" is for vital medicines, the "E" is for essential medicines and the "N" is for non-essential medicines (or "D" for desirable). For the purpose of this paper, the VEN nomenclature will be used. The classification for each of these medications is highly subjective, but typically the vital medications are those where the cost of a stock out is typically very high. These are medications that can save someone's life, have severe withdrawal side effects or are important to maintain the standard level of care (WHO, 2012). These are the drugs that must be available at all times. The Medications in the "E" category are still vital to have, but are not as critical. They may be rarely used or have substitutes or alternatives that do not degrade patient outcomes. All others are in the "N" category. These are the medications that are nice to have, but can be survived without (WHO, 2012) (Devani et al., 2010). Table 1 is one way to determine how to differentiate between the different categories. Controlled substances usually receive a lot more scrutiny and are the only classification of medications for which there is an accurate inventory readily available electronically and manually. Considering the regulations required for controlled substances, denoted as schedule II-V, these medications might be considered as vital or essential, simply due to the amount of scrutiny and documentation required for maintaining even a small amount of inventory.

Table 1.    Sample VEN Guidelines. Source: WHO (2012).

| Characteristic of Medicine or Target Condition | Vital | Essential | Non-essential/Desirable |
|---|---|---|---|
| **Occurrence of target Condition** | | | |
| Persons affected (Percent of Population) | >5 | 1-5 | <1 |
| Persons Treated (number per day at average health center) | >5 | 1-5 | <1 |
| **Severity of Target Condition** | | | |
| Life-Threatening | Yes | Occasionally | Rarely |
| Disabling | Yes | Occasionally | Rarely |
| **Therapeutic effect of medicine** | | | |
| Prevents serious Disease | Yes | No | No |
| Cures serious disease | Yes | Yes | No |
| Treats minor, self limited symptoms/conditions | No | Possibly | Yes |
| Has proven efficacy | Always | Usually | Possibly |
| Has un-proven efficacy | Never | Rarely | Possibly |

Using the ABC Analysis or the VEN Analyses may not be the right way to differentiate medications for every pharmacy. The ABC analysis really is suited for pharmacies that are trying to reduce inventory costs. The VEN analysis lends itself better to an NGO or country that has significant constraints on their medication budget. It is a very good tool for those hospitals that have a restrictive formulary. There is also the option to combine these to analyses into the ABC-VEN matrix analysis (Devani et al., 2010). This is performed by assigning each medication an "A," "B," or "C" from the ABC analysis and a "V," "E," or "N" resulting in nine categories: "AV," "AE," "AN" and so on. These categories are then divided into Category I, II, and III as shown in Table 2 (Devani et al., 2010).

Table 2.    ABC-VEN Categorization.
Adapted from Devani et al. (2010).

| Category | ABC-VEN Classification |
|---|---|
| I | AV, AE, AN, BV, CV |
| II | BE, BN, CE |
| III | CN |

This classification opens up the most important category of medications, making it important to track and stock some of the B and C items. This is important because with this model, the acquisition costs are not the sole basis for dividing the medications. The VEN method takes into account the intangible shortage cost to the patient or society if they cannot get the medication immediately.

### 4. Methods to Manage Inventory

Much of what has been stated previously has been industry standards and recommendations. But one of the biggest differences between managing a civilian pharmacy compared to a military pharmacy is money and profit. The Navy spends $500M in acquisition costs of medications worldwide (Boyle, 2013); much of that budget is spent in only a couple of the Navy's largest facilities. Pharmacies have three basic approaches of managing inventory: visually, sometimes referred to as "looking it over," periodically, or physical inventory, and continuously, (Ali, 2011) *(Elements*, 2013).

#### a. *Visual Review Method*

The visual method is as it sounds; the supply personnel will visually inspect each item and once it falls below a certain level, it will get reordered (Bouldin et al., 2011). In this system, the pharmacist will often have a "want book," which is a notebook where the pharmacy staff keeps track of medications that need ordering throughout the day, and is very common in smaller pharmacies (Bouldin et al., 2011). Typically as the pharmacy fills prescriptions the staff will make note of a low medication or puts the item's barcode in the notebook. At the end of the day an order is generated using the notes (Bouldin et al., 2011). Some of the benefits of this system include low cost of implementation, convenience, and informality (Bouldin et al., 2011). This is an ideal system for a small pharmacy without much inventory; however there is a huge risk of stock outs due to oversight or missing an order.

### b.      *Periodic Review Method*

The periodic method is very similar, except that the supply staff inspects the inventory at preset time periods such as weekly or monthly. It is even possible to have multiple periods, fast moving items might be re-ordered daily while slower moving items only weekly or monthly. Like the visual system, the periodic system, orders when the stock falls below the reorder point (*ROP*). This method is a little more formal than the visual, which allows for some data to be generated. With this data, the manager can do minimal analysis. The benefits are that it is also inexpensive to implement and the limited data generation (Bouldin et al., 2011). The disadvantages are the time investment needed as well as the risk of stock outs and greater safety stock.

### c.      *Continuous Review Method*

The last and most efficient method is continuous inventory, known in the pharmacy literature as a perpetual inventory system. A majority of civilian pharmacies use a computer based continuous inventory system (Ingersol, 2015) but a continuous review can be done on a small number of items by hand (Bouldin et al., 2011). With continuous inventory systems, inventory is tracked at the level of sale (dispensing) and a real time inventory can be known. The system can place an order once the inventory gets below the *ROP*. In addition to re-ordering and keeping track of the inventory, a continuous system can give detailed analyses with all of the data it collects, such as average inventory, variations in demand or any kind of seasonality (Bouldin et al. 2011).

This is the best inventory management system of all the choices. It can save money by reducing inventory, provide a total value of the inventory in stock, and reduce the risk of stock outs compared to the other systems. An added benefit is the continuous system should reduce the work spent walking the shelves and entering reorder information (Willard, 2012), allowing for those resources to be used in other places. The biggest disadvantage of the continuous system is the cost.

For many pharmacies, the system that is best for the pharmacy largely depends on the pharmacy itself, specifically its budget. The periodic/visual methods are the least expensive, at least in the start up phase and for smaller pharmacies, but they may be at an

increased risk for error. The risk of stock-out increases if the supply staff inadvertently misses an item that is below the *ROP*. This may put the patient in danger, and is also bad for business. There are strategies for minimizing the safety impact to patients; such as partially filling a prescription to ensure they have enough medication until the pharmacy is resupplied. If this happens often, the patient is likely to look for another pharmacy. There are several benefits of utilizing a continuous inventory system beyond the obvious of saving personnel costs. It can help the pharmacy identify lost items due to shrinkage, help with reporting (financial statements as well as an easy way to view demands and utilization), help track turnover rates, and even help with forecasting (Ingersol, 2015).

## 5.    How Much to Order?

### a.    *Economic Order Quantity (EOQ)*

The economic order quantity is a mathematical solution to minimize costs associated with ordering and holding inventory. AT larger and larger order quantities of an item, carrying costs will increase due to the increased inventory (Bouldin et al., 2011). Conversely, as the order quantity increases the procurement cost will decrease due to decreased orders; the EOQ takes these two costs and determines the quantity to order at which the total cost of managing inventory is the lowest (Bouldin et al., 2011). Figure 1 shows this relationship graphically.

Figure 1. Economic Order Quantity. Source Seftil (2016).



The holding cost is an approximation of a variety of factors; for a pharmacy, the average annual holding cost is 20–30% of the value of the inventory (National Community Pharmacists Association, 2008). This means that a pharmacy that has an average inventory value of $1 million will pay about $200-300 thousand to maintain that inventory. Calculating the EOQ for each item and then maintaining and updating the levels as demands shift can be a very tedious process. Fortunately technology can take care of this task, freeing up the pharmacy staff to take care of patients and other tasks (Bouldin et al., 2011). The limitations of the EOQ method include assumptions of continuous use and prices without fluctuations (Bouldin et al., 2011).

### b. *Joint Ordering Strategy*

The purpose of joint ordering is to take a group of coordinated items and order them in as one whole unit (Aksoy & Erenguc, 1988). This system of inventory management has many different versions, but one thing they all have in common is that they take items with a large set-up cost or a high fixed cost per order and combine orders resulting in significant savings (Pantumsinchai, 1992). The execution of joint ordering will largely be dependent on the policies of the individual site that the organization uses to manage inventory; when the site determines the order all of the items in the group (Pantumsinchai, 1992). The reorder point is dependent on the amount of risk the pharmacy is willing to take, as well as the holding and shortage costs of the items. A couple examples of ordering triggers are: once one item is below its *ROP*, or the re-order

14

can trigger once several items are below the *ROP*. With this system, the item(s) that trigger the replenishment are ordered normally, but for the remaining items the benefit comes with procuring medications at a reduced set-up cost (Pantumsinchai, 1992). This system works best when using the (S, s) method of inventory management, where the quantity ordered is variable based on the difference between the maximum inventory level (S) and the inventory level when the order is placed (Pantumsinchai, 1992). This type of inventory management system is difficult to manage without the use of computer-assisted inventory, but can also be used with a modified EOQ type method (Aksoy & Erenguc, 1988). With the modified EOQ system, rather than optimizing each individual item, a group is optimized so that the order quantities correspond with the average demand so that each item should need to be ordered at approximately the same interval (Aksoy & Erenguc, 1988).

### 6.    When to Re-order

Determining when to reorder an item largely depends on the amount of safety stock needed or amount of risk of stock out management would like to assume. The demand during lead-time is also important in determining when to reorder (Krajewski & Ritzman, 1996, p. 554–555). Service level is the probability that an item will not run out of stock in an order cycle (Krajewski & Ritzman, 1996, p. 554–555) and it is used to manage the risk of stock outs. Service levels are usually given in percentages and the higher the percentage the lower the risk of stock outs. Having a higher service level comes at a cost; more inventory is required, which means paying more holding cost. Different managers might determine with different service levels, but they all must consider the objective costs of having no inventory and maintaining extra inventory as well as the subjective non-monetary costs into account. Determining the appropriate service level is a balancing act, management must decide if based on what they think is best for their organization.

THIS PAGE INTENTIONALLY LEFT BLANK

# III.   METHODS

This chapter will focus on how this study was completed. It will discuss the source of the data being analyzed, and how the ABC analysis was completed, and how the VEN categorization was applied to the data.

## A.   DATA SOURCE

### 1.   Demand Data

This study focuses on one pharmacy, NMCSD Pharmacy, and the data comes directly from their pharmacy. Currently, there is no good way to extract the demand of medications in enough detail from their computer pharmacy system, Composite Health Care System (CHCS). One of the benefits of CHCS is its ability to store and report data, however it is an old, non-Windows based system that requires a lot of specialized knowledge to operate to its full potential. CHCS does have an inventory management feature as well as an inventory-reporting tool (Science Applications International Corporations (SAIC), 1996). Another option to get demand data is to use the Drug Utilization Review reports, which divides the data into individual prescriptions per day. The last option of the pre-set reports is the product activity report (PAR). This report is very useful in gathering data for one or two medications for a small amount of time, but must be run for each day to get daily demand and for each medication individually. That is 365 reports needed per medication. Ultimately the data for this project came from an ad hoc report that made the PAR report include the totals for the specified time (one day) and all of the medications dispensed for that day (Science Applications International Corporations (SAIC), 1996). The difficulty with ad hoc reports is they require special training to build (Science Applications International Corporations (SAIC), 1996) and not all sites may have someone with that training.

The specialized PAR report included a total number of units dispensed during the specified time period as well as the unit cost of the medication. The medications were identified by internal entry number (IEN), a unique number that identifies each unique item within the system. Each of these 365 reports contained a number of items as small as

200 up to 700 different items used for that day which were individually imported into Microsoft Excel. The relevant data was filtered and combined into one large table using the excel ad-in "ablebits." Ablebits is a tool that will merge 2 tables adding the extra columns with the new data and extra rows for the data that had not been used yet. The resulting table included every medication used for the year, approximately 2,300 medications, and the demand separated into each day.

### 2. Procedural Data

The procedural data used in this study was obtained during a site visit to NMCSD pharmacy, electronic correspondence with the supply staff, and the author's personal knowledge of the site gained from working there as a pharmacist for several years. The information gathered directly from NMCSD's supply staff included, but is not limited to:

- Number of orders placed per year
- Number of items per order
- Time spent on the order from start to finish
- How the order was generated

## B. CATEGORIZATION OF MEDICATIONS

### 1. ABC Categorization

Setting up an ABC analysis is easy using a spreadsheet program. It requires ranking the different products by each individual percentage of the total value of the inventory and graph the cumulative percentage on the Y-axis and the total number of products on the X-axis. To find the percentage of use, multiply the demand (units purchased) over a given period of time by the unit cost, and then divide the cost per period of time by the total amount spent and graph (WHO, 2012). An example of the table and graph can be seen in Table 3.

Table 3.    ABC Analysis from NMCSD. Adapted from WHO (2012).

| Drug Name | Unit Cost | Total Demand (Units) | Total Cost | % total | Cumulative % Total | Category |
|---|---|---|---|---|---|---|
| TRUVADA 200MG/300MG ORAL TAB | $50.92 | 87,498 | $4,455,203.72 | 4.25% | 4% | A |
| FLUTICASONE (FLONASE) 50MCG NAS INH 16GM | $64.94 | 47,400 | $3,078,156.00 | 2.94% | 7% | A |
| LANTUS SOLOSTAR 300U/3ML PREFILLED PEN | $51.99 | 55,368 | $2,878,656.14 | 2.75% | 10% | A |
| ABOBOTULINUMTOXINA(DYSPORT)300UNITS INJ | $147,336.77 | 16 | $2,357,388.32 | 2.25% | 12% | A |
| RIZATRIPTAN (MAXALT) 10MG ORAL TABLET | $480.21 | 4,659 | $2,237,298.39 | 2.13% | 14% | A |
| NORELGESTROMIN/ETHIN.ESTRADIOL PATCH--TD | $15.85 | 5,025 | $79,629.50 | 0.08% | 80% | B |
| APIXABAN(ELIQUIS)2.5MG ORAL TAB | $1.77 | 44,884 | $79,499.54 | 0.08% | 80% | B |
| ALBUTEROL SULFA(PROAIR HFA)90MCG INH HFA | $6.84 | 11,588 | $79,261.92 | 0.08% | 80% | B |
| AUGMENTIN XR AMOX/POT 1000-62.5MG TAB--P | $2.99 | 26,358 | $78,751.11 | 0.08% | 80% | B |
| ERLOTINIB HCL(TARCEVA) 150MG ORAL TAB | $118.68 | 660 | $78,331.44 | 0.07% | 80% | B |
| ARIPIPRAZOLE (ABILIFY) 30MG TAB | $19.39 | 854 | $16,563.05 | 0.02% | 95.00% | C |
| AMINOCAPROIC ACID (AMICAR) 500MG TAB | $6.02 | 2,748 | $16,546.17 | 0.02% | 95.02% | C |
| DEFERASIROX (EXJADE) 125MG ORAL TAB | $14.50 | 1,140 | $16,526.33 | 0.02% | 95.03% | C |
| EPOETIN ALFA (PROCRIT) 20,000 U/ML INJ | $294.97 | 56 | $16,518.13 | 0.02% | 95.05% | C |
| PALIPERIDONE (INVEGA) 6MG ER TAB | $13.30 | 1,238 | $16,469.53 | 0.02% | 95.07% | C |

## 2.    Vital, Essential, Non-Essential

Classifying each medication as vital, essential, or non-essential is completely independent of the ABC analysis and must be done separately. Each pharmacy would divide their formulary based on their own needs and criteria. For this study each medication was divided based on four major criteria seen in Table 4.

Table 4.    NMCSD Criteria for VEN Classification.
Adapted from WHO (2012).

| Characteristic of Medication or Target Condition | Vital | Essential | Non-Essential |
|---|---|---|---|
| **Demand** | | | |
| Days used at NMCSD | >260 days | 100<days<260 | <100 days |
| **Miscelaneous** | | | |
| Prevents serious Disease | Yes | No | No |
| Controlled Substance | CII | CIII-IV | CV |
| Importance of Missed doses | Can't miss | OK | PRN |

The number of days used at NMCSD and the controlled substance classification criteria are very objective and require no interpretation. The other two, the prevention of serious disease and the importance of missed doses, require knowledge of the medications that they are classifying or the conditions the medications are treating.

Dividing each medication into vital, essential, and non-essential medications would be a decision for the Pharmacy and Therapeutics Committee (P&T) (WHO, 2012) and not only a single pharmacist or doctor. However, for this study the author used his professional judgment and experience to determine if the medications prevented serious disease or if a missed dose would have serious consequences.

## C.    NECESSARY EQUATIONS

### 1.    Economic Order Quantity

With the EOQ inventory management method, the order cost ($S$) is the fixed cost of placing an order for just one item at a time and for this study the same $S$ is used for all medications ordered. The equation used to determine EOQ follows.

$$EOQ = \sqrt{\frac{2DS}{hC}}$$

Where:

$D$ = item annual demand
$S$ = order Cost
$C$ = item Cost
$h$ = holding Cost, as a percentage of the cost

### 2.    Joint Ordering Strategy

With the joint order strategy, the goal is to find the optimal number of orders per year ($n^*$) and work backwards to determine the optimal joint order quantity ($Q_i$). One big difference between the joint ordering strategy compared to the *EOQ* method is the break-up of the costs into the common order cost ($S$) and the item specific costs ($s$). The combined order cost ($S^*$) is $S$ plus the item specific cost of every item in the group. For example in a pharmacy walking the shelves to generate an order is a common ordering cost and putting the medications away after the order has been received is a item specific cost. Using $n^*$ the optimal joint order quantity for each individual item can be determined using the equations provided (Chopra & Meindl, 2013). The $Q_i$ is simply the annual demand for an item divided by the calculated $n^*$ (Chopra & Meindl, 2013).

$$S^* = S + s_1 + s_2 + \dots + s_n$$

$$n^* = \sqrt{\frac{D_1 * h * C_1 + D_2 * h * C_2 + \dots + D_n * h * C_n}{2S^*}}$$

$$Q_i = \frac{D_i}{n^*}$$

Where:

$Q_i$ = joint order quantity for Item i
$S^*$ = total order cost
$S$ = common order cost
$s$ = item specific order cost
$D_i$ = annual demand for Item i
$n^*$ = optimal number of orders per year

### 3. Reorder Point

Two components make up the *ROP*, the demand during lead-time and the amount of safety stock needed. Many formulas can be used to determine this, taking into account the variability in demand as well as variability in lead-time. Fortunately at NMCSD the lead-time is relatively constant with almost no variability, therefore this model assumes no variability in lead-time. The formula used to determine *ROP* is

$$ROP = d * LT + (Z * \sqrt{LT} * \sigma)$$

Where:

*ROP* = re-order point
$d$ = daily demand
$LT$ = lead time in days
$Z$ = number of standard deviations from mean (Z score)
$\sigma$ = standard deviation of daily demand

THIS PAGE INTENTIONALLY LEFT BLANK

# IV.   ANALYSIS

## A.   ABC ANALYSIS

The ABC analysis was performed to differentiate the 2,300 SKUs that the pharmacy carries. For the purpose of this paper, the A items are the most important either as a result of the demand or because they are expensive in relation to the other items. The B and C items account for a much smaller percentage of the overall pharmacy inventory budget. In this study, the A items represent 80 percent of the total budget, the B items are only 15 percent and the C items include the last 5 percent of the budget. However, there are only 241 items in the A category, 426 in the B, and 1677 in C as shown in Table 5 or graphically in Figure 2. The percentages of cost assigned to each group were assigned arbitrarily based on being a number that is a factor of five and the number of items that would correspond with the assignment.

Table 5.    NMCSD ABC Analysis Breakdown.

| Category | Percent of Cost | Number of SKUs | Percent of SKUs |
|----------|-----------------|----------------|-----------------|
| A | 80 | 241 | 10 |
| B | 15 | 426 | 18 |
| C | 5 | 1677 | 72 |

Figure 2.  NMCSD ABC Analysis (July 2015–July 2016).



## B.     VEN CATEGORIZATION

A unique aspect of health care inventory and especially medications is that cost and demand are not always the best indicators of what is most important to manage inventory. Sometimes the subjective stock out cost of a medication is significantly high and that item must be managed as closely as an A item, even if it is a C item. As mentioned earlier, a committee would do this assignment into Vital, Essential, and Non-Essential items locally or as an organization. The results of this analysis can be seen in Table 6.

Table 6.     NMCSD VEN Analysis Breakdown.

| Category | Number of Medications |
|----------|-----------------------|
| V | 336 |
| E | 476 |
| N | 1531 |

## C.    ABC-VEN CATEGORIZATION

The ABC analysis is not enough to use when evaluating the inventory of a pharmacy and should be used in conjunction with a tool that takes non-monetary factors into consideration. The VEN analysis tool fills this gap. The results of combining the ABC analysis and the VEN analysis can be seen in Table 7. Category I medications replace A as the most significant category to watch. Category I medications will be used to conduct the rest of the analysis of this study. It is assumed that all benefits achieved from modifying the Category I medications will apply to Category II and III because the are used infrequently or represent such a small fraction of the overall acquisition costs. An added benefit of this method of categorization is it breaks the Category I medications into five joint ordering groups: AV, AE, AN, BV, and CV.

Table 7.    Results of Combining ABC and VEN Analysis.

| | AV | AE | AN | BV | BE | BN | CV | CE | CN | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Category I | 102 | 82 | 57 | 96 | | | 138 | | | 475 |
| Category II | | | | | 156 | 174 | | 238 | | 568 |
| Category III | | | | | | | | | 1300 | 1300 |
| Total | 102 | 82 | 57 | 96 | 156 | 174 | 138 | 238 | 1300 | 2343 |
| | 241 | | | 426 | | | 1676 | | | |

## D.    DEMAND ANALYSIS

Both models evaluated require a few key pieces of information: the demand, holding cost, unit cost and ordering cost. Much of that information is given in the data and the holding cost of inventory in a pharmacy is 20% (National Community Pharmacists Association, 2008). One thing that must be determined is the ordering cost.

### 1.    How Much to Order

### a.    *Ordering Costs*

The information about the time spent on each activity involved in ordering was determined from email correspondence with the supply officers at NMCSD. Also missing

in this analysis was the fixed shipping and handling fee that would be a fixed cost charged per order. This cost was not known by anyone interviewed.

(1)     Supply Staff

The NMCSD is currently made up of three different classifications of employees, General Schedule (GS) pharmacists and technicians and military technicians or Corpsmen. The pay of these individuals is based on their rank or GS grade and step and is variable based on the people who fill these positions. The assumptions made to calculate the ordering costs is that the GS Pharmacist is a grade of 13 step five, the GS technicians have a grade of nine step five, and the corpsman is an E3 with over three years. Locality pay was also included in the calculation of the costs of these workers. Their salary breakdown can be seen in Table 8.

Table 8.     NMCSD Supply Staff Salary Breakdown, Adapted from San Diego
Locality Area-General Schedule Localities (2016), Military Pay Chart for
2016 (2016), Defense Travel Management Office (2016).

| Job Type | salary/year | Daily wage | Hourly Wage |
|---|---|---|---|
| GS Pharmacist* | $104,392.00 | $417.57 | $52.20 |
| GS technician** | $60,533.00 | $242.13 | $30.27 |
| Military Tech*** | $51,768.00 | $207.07 | $25.88 |

*Assuming GS13 Step 5, **Assuming GS9 Step 5, ***Assuming E3 >3 years with dependents.

(2)     Ordering Tasks

The personnel costs associated with the ordering cost can be broken into three categories which Table 9 summarizes

- **In-processing of the order**—This includes verifying the invoice with the medications that were included in the order and putting the medications away. Each order takes two technicians four hours to complete (Vancheri, 2016).

- **Walking the shelves/Order building**—This task the technicians walk the shelf visually inspecting each item to determine if it needs reordering. If a medication needs to be reordered the technician scans the barcode adding the item to the order and counts the medication to determine how much to

order. This task is done daily and usually takes three technicians three hours to complete (Vancheri, 2016).

- **Managing the Order**—This task is probably the hardest to quantify and counts as the catch all in the ordering process. This includes monitoring the orders insuring that all items needed are actually ordered. If there is a shortage of an item the pharmacy supply staff search the different generics looking for an equivalent. They monitor drug shortages ensuring that once a medication is available again, it is reordered promptly. This task is done daily and it was estimated that it takes two technicians five hours and one pharmacist two hours daily (Vancheri, 2016).

Table 9.    Order Cost Breakdown Adapted from (Vancheri, 2016).

| Task | Number of Techs | Number of Pharmacists | Tech hours required/order | Pharmacist Hours | Cost/order |
|---|---|---|---|---|---|
| In-processing of Order | 2 | 0 | 4 | 0 | $242.13 |
| Walking shelves/Building Order | 3 | 0 | 3 | 0 | $272.40 |
| Managing Order | 2 | 1 | 5 | 2 | $407.06 |
| Total: | | | | | $921.59 |

(3)    Determining Common Order Costs ($S$) and Total Order Cost ($S^*$)

The first task of determining the order cost was deciding what is a common order cost and what is item specific. To guide this analysis, a common cost was any cost that would need to be paid if only one item was ordered. The first common cost is "walking the shelves/building the order." This is a common cost because the supply staff could potentially walk the shelves to build the order and only need one item. This is a very hypothetical situation to help build the model. Managing the order is a common cost because this cost is fixed.

For the *EOQ* model, *S* is the cost of managing the order plus building the order. To make the scenario a little more realistic, the cost of managing the order for the EOQ method is divided by six. Twelve man-hours for a one-item order is not very realistic, however two man-hours managing an order is a reasonable amount of time. The In-processing of the item for a one-item order is negligible because it would take almost no time to complete. The resulting S is $340.24 per order.

27

The $S^*$ in the joint ordering strategy is a little more complex. No manipulation of the order building or order management cost is necessary The common cost ($S$) is the same for all five joint order groups and is $679.46 when using the periodic system. If a continuous review system were to be used, this would eliminate the order building cost reducing $S$ to $407.06. The item specific cost for each category prorated cost of in-processing the order. An average order for NMCSD contains approximately 177 different SKUs (Vancheri, 2016). To get the per item in-processing cost the $242.13 in-processing cost was divided by 177 to equal $1.37 per item. For each group, the total number of items in the grouping is multiplied by $1.37 for the total item specific cost for that grouping. For the AV items in the item specific cost is $1.37*102 items and equals $139.53. When added to the $679.46 common cost the $S^*$ is $818.99. The ordering costs for all groups using the periodic system and continuous system are summarized in Tables 10 and 11 respectively.

Table 10.    Summary of Order Costs at NMCSD, Periodic Review. Adapted from Chopra & Meindl, (2013).

| Ordering Cost | EOQ | AV | AE | AN | BV | CV |
|---|---|---|---|---|---|---|
| Common (S) | $340.24 | $679.46 | $679.46 | $679.46 | $679.46 | $679.46 |
| $S_{av}$ | | $139.53 | | | | |
| $S_{AE}$ | | | $112.17 | | | |
| $S_{AN}$ | | | | $77.97 | | |
| $S_{BV}$ | | | | | $131.33 | |
| $S_{CV}$ | | | | | | $190.15 |
| Total | $340.24 | $818.99 | $791.63 | $757.43 | $810.78 | $869.60 |

Table 11.    Summary of Order Costs at NMCSD, Continuous Review.  Adapted from
Chopra & Meindl, (2013).

| Ordering Cost | EOQ | AV | AE | AN | BV | CV |
|---|---|---|---|---|---|---|
| Common (S) | $203.53 | $407.06 | $407.06 | $407.06 | $407.06 | $407.06 |
| $S_{av}$ | | $139.53 | | | | |
| $S_{AE}$ | | | $112.17 | | | |
| $S_{AN}$ | | | | $77.97 | | |
| $S_{BV}$ | | | | | $131.33 | |
| $S_{CV}$ | | | | | | $190.15 |
| Total (S*) | $203.53 | $546.59 | $519.23 | $485.03 | $538.38 | $597.21 |

### b.    *Inventory Models*

As discussed in the methods chapter, determining the *EOQ* or $Q_i$ of an item is a simple math problem when you know the holding cost, unit cost, demand and order cost. The $Q_i$ is made a little more difficult because the common order cost and item specific order cost must be known. The standard holding cost for a pharmacy is approximately 20–30% (National Community Pharmacists Association, 2008) and for the purpose of this model 20% was used for all models. The order costs can be determined by referencing Tables 10 and 11. One important assumption to remember is that in the *EOQ* model, all items are ordered independently and the order cost is based on a one-item order.

To determine which system is best, the overall order cost should be compared across all of the models. In this study *EOQ* and $Q_i$ each with periodic and continuous review have been compared and their total annual costs are shown in Table 12. For the initial analysis, only the order cost and the holding cost of the average inventory will be compared. The holding cost associated with safety stock will not be included because this is cost is not relevant when deciding if periodic or continuous review is best. Important to note that in most cases the quantities derived using the *EOQ* or the $Q_i$ method will not be available for purchase in those quantities. Rounding up or down to the nearest multiple of the nearest bottle size will not impact the cost much. For example, if the *EOQ* is 637,

order 700 tablets if the medication comes in bottles of 100 or 690 if the medication comes in bottles of 30.

Table 12.    NMCSD Pharmacy Annual Cost Analysis of Category I Medications.  Adapted from Chopra & Meindl, (2013), Bouldin et al., (2011).

| | AV | | AE | | AN | |
|---|---|---|---|---|---|---|
| | EOQ | Joint | EOQ | Joint | EOQ | Joint |
| Periodic Review | | | | | | |
| Holding Cost | $343,950.11 | $61,749.90 | $219,960.32 | $41,431.94 | $154,276.32 | $34,337.66 |
| Ordering Cost | $343,950.11 | $61,749.90 | $219,960.32 | $41,431.94 | $154,276.32 | $34,337.66 |
| Total Cost | $687,900.22 | $123,499.81 | $439,920.63 | $82,863.89 | $308,552.63 | $68,675.33 |
| Continuous Review | | | | | | |
| Holding Cost | $266,020.15 | $50,446.18 | $170,123.15 | $33,554.80 | $119,321.40 | $27,477.96 |
| Ordering Cost | $266,020.15 | $50,446.18 | $219,960.32 | $33,554.80 | $119,321.40 | $27,477.96 |
| Total | $532,040.30 | $100,892.37 | $390,083.46 | $67,109.60 | $238,642.80 | $54,955.92 |
| | BV | | CV | | Total Annual Cost | |
| | EOQ | Joint | EOQ | Joint | EOQ | Joint |
| Periodic Review | | | | | | |
| Holding Cost | $109,462.93 | $17,705.21 | $359,327.35 | $3,464.21 | | |
| Ordering Cost | $109,462.93 | $17,705.21 | $359,327.35 | $19,259.74 | | |
| Total Cost | $218,925.87 | $35,410.42 | $718,654.70 | $22,723.95 | $2,373,954.06 | $333,173.40 |
| Continuous Review | | | | | | |
| Holding Cost | $84,661.54 | $14,427.62 | $277,913.32 | $2,725.77 | | |
| Ordering Cost | $84,661.54 | $14,427.62 | $277,913.32 | $16,810.01 | | |
| Total | $169,323.08 | $28,855.24 | $555,826.63 | $19,535.78 | $1,885,916.28 | $271,348.92 |

Table 12 reveals that joint ordering has a significant advantage in all groups of Category I medications. Grouping orders results in about a $1.5-2 million savings compared to ordering each item individually. This model estimates that there would be a savings of approximately $62,000 annually if NMCSD should use a continuous review system over a continuing with the periodic review.

2.      Sample Problems

Using a small sample of three medications the sample problems will illustrate how the costs in Table 12 were derived. Table 13 shows the summarized collected data of three medications that were used to complete this analysis. Refer back to the *EOQ* and $Q_i$ formulas provided in Chapter 3 to calculate these quantities. Tables 14 and 15 show a

step-by-step example of how to calculate total cost using the given data in Tables 10 and 13. The calculation of $S^*$ and $n^*$ is shown in the equations directly following Table 15. The results of this small sample is joint ordering is $2,813 less expensive than ordering individually with the EOQ model.

Table 13.    NMCSD Sample Data Adapted from Chopra & Meindl, 2013

| Drug Name | Unit Cost | Average daily demand (Units) | Annual Demand (Units) | SD |
|---|---|---|---|---|
| FLUCONAZOLE (DIFLUCAN) 200MG TAB | $15.68 | 36 | 13,198 | 70.29 |
| FLUOXETINE (PROZAC) PO 10MG CAP | $6.05 | 91 | 33,218 | 110.81 |
| SITAGLIPTIN (JANUVIA) 25MG ORAL TAB | $12.99 | 42 | 15,280 | 75.77 |

Table 14.    Economic Order Quantity Example, Periodic Review Adapted from Chopra & Meindl, 2013.

| Drug Name | EOQ | Average Inventory | Cycle Stock Holding Cost | Orders per year | Annual Order Cost |
|---|---|---|---|---|---|
| FLUCONAZOLE (DIFLUCAN) 200MG TAB | 1,692 | 1692/2=846 | 846*$15.68*20%= $2,653 | 13,198/1,692 =7.8 | $340*7.8= $2,652 |
| FLUOXETINE (PROZAC) PO 10MG CAP | 4,321 | 4321/2=2161 | 2,161*$6.05* 20%=$2,614 | 33,218/4,321 =7.7 | $340*7.7= $2,618 |
| SITAGLIPTIN (JANUVIA) 25MG ORAL TAB | 2,001 | 2001/2=1000 | 1,000*$12.99 *20%=$2,598 | 15,280/2,000 =7.6 | $340*7.6= $2,584 |
| Subtotal | | | $7,865 | | $7,854 |
| Total Cost | | | | | $15,719 |

Table 15.    Joint Order Quantity Example, Periodic Review Adapted from Chopra & Meindl, 2013.

| Drug Name | Di*Ci*h | Q$_i$ | e Stock Holding | Order Cost |
|---|---|---|---|---|
| FLUCONAZOLE (DIFLUCAN) 200MG TAB | 13,198*$15.68 *20%=41,388 | 13,198/9.4 =1,404 | 1,404/2*$15.68 *20%=$2,201 | |
| FLUOXETINE (PROZAC) PO 10MG CAP | 33,218*$6.05* 20%=40,193 | 33,218/9.4 =3,533 | 3,533/2*$6.05* 20%=$2,137 | |
| SITAGLIPTIN (JANUVIA) 25MG ORAL TAB | 15,280*$12.99 *20%=39,697 | 15,280/9.4 =1,625 | 1,635/2*$12.99 *20%=$2,147 | |
| SubTotal | 121,278 | | $6,485 | 9.4*683.11=$6,421 |
| Total | | | | $12,906 |

$$S^*=\$679+1.37+1.37+1.37 \quad n^*=\sqrt{\frac{41,388+40,193+39,697}{2*683.11}}=9.4$$

31

### 3. When to reorder

Due to the relatively short lead-time to resupply inventory, the need for safety stock is greatly diminished. However, the high variability in demand negates the short lead-time advantage and necessitates at least some safety stock. The amount of safety stock at NMCSD or any pharmacy is up to the senior management and must balance the holding cost with the cost of stock outs. For this study, the service level of the items is determined by the VEN categorization of medications. Vital medications have a service level of 95 percent, essential medications have a service level of 90 percent and the non-essential medications have a service level of 85 percent. Once the *ROP* is determined a policy must be considered to decide when to reorder.

One consideration is that once any item in the reorder group is below the *ROP*, the entire group is reordered using the $Q_i$ quantity for each item. The benefit of this policy is that it minimizes the risk of stock-outs because the whole group of medications is reordered when only one item is below the *ROP*. The potential disadvantage of this policy is that this could potentially create a temporary over-stock situation increasing the holding cost. In the long run, over a year, all of the ordered inventory should be used. Another possibility is to re-order once a certain percentage of medications in the group are below the order point. This policy would significantly increase the risk of a stock out.

# V. CONCLUSIONS AND RECOMMENDATIONS

## A. SUMMARY

Inventory management is not a one size fits all decision that can be made. Sometimes even the optimal solution may not be the right one if the constraints are present. The best way to analyze an inventory management policy is to start by deciding what to analyze. Using an ABC analysis can help differentiate the items that really need to be focused on to save money and time from those that really do not impact much. Used alone, the ABC analysis is good for some industries, but in the medical community, the most important medications are not always the ones with the highest demand or cost the most money. Patient safety concerns or accreditation requirements are just two reasons why it may be important to upgrade a medication categorized as a B or C into a more closely observed status. This shows that the VEN classification system when used in combination with the ABC analysis may provide a better picture on the inventory items that should be focused on.

Once the items to focus on has been decided the analysis of how much and when to order and when can be done. This is accomplished first by deciding which system will be used: periodic, continuous, or a hybrid system. Using the *EOQ* formula or joint order formula the optimal re-order quantities can be calculated for a decision. The easy part is then deciding when to re-order, but this is highly dependent on the service level that is decided upon and may be different for different managers.

## B. CONCLUSION

This study has differentiated NMCSD's medications into three categories using a hybrid of the ABC Analysis and VEN categorization, used personnel salaries to determine ordering costs and separated these into common and item specific costs and compared an *EOQ* with a joint ordering model. No matter which inventory system that is decided upon, the decision should be made based on it would impact the Category I medications. While the Category II and III medications would be impacted slightly, the largest benefit would come from Category I. This study determined that the joint ordering

33

method was 84 percent less expensive than single item *EOQ* ordering and continuous review was 18 and 19 percent less expensive than periodic review when compared to joint ordering and the *EOQ* model respectively. Figure 3 shows these cost savings graphically.

Figure 3.  Total Costs (Holding + Order) of Category I Medications at NMCSD.
Adapted from Chopra & Meindl, (2013).



Due to the assumptions made to create the *EOQ* model, it is overestimating the order costs and the difference between joint ordering and the *EOQ* model are likely closer in cost than the analysis shows. Another weakness when considering the *EOQ* model is that many of the items are so inexpensive that the order quantity becomes almost a full year's demand worth, making it not a realistic number. In this model a continuous review system is less expensive because it decreases the order cost by about $270 each order placed. This is the monetary cost of order building, it does not include the subjective costs of reallocating the supply personnel during those times to help with patient care and thus increasing patient safety and reducing wait times.

This study arranged the order groups based on their ABC-VEN classification, however this is not the only way to do this. An alternative would be to arrange the groups based on their coefficient of variation (CV) or simply by their demand. The results that this study determined can be seen in Tables 16 through 20.

Table 16.     Continuous Review AV Medication Results.  Adapted from Chopra & Meindl, (2013), Krajewski & Ritzman, (1996).

| | n* | 75.4 | | | Service Level | 95% | |
|---|---|---|---|---|---|---|---|
| Medication Name | JOQ | Safety Stock | Reorder Point | Medication Name | JOQ | Safety Stock | ROP |
| TRUVADA 200MG/300MG ORAL TAB | 948 | 327 | 566 | DERMA-SMOOTHE/FS OIL-FLUOCINOLONE 0.01%- | 1,435 | 599 | 961 |
| FLUTICASONE (FLONASE) 50MCG NAS INH 16GM | 514 | 248 | 378 | ZOLPIDEM TARTRATE (AMBIEN) 5 MG ORAL TAB | 633 | 196 | 356 |
| LANTUS SOLOSTAR 300U/3ML PREFILLED PEN | 600 | 238 | 389 | MOXIFLOXACIN HCL (VIGAMOX) 0.5 % OPHTHAL | 123 | 177 | 207 |
| RIZATRIPTAN (MAXALT) 10MG ORAL TABLET | 50 | 38 | 51 | EPINEPHRINE(EPIPEN 2-PAK)0.3MG/0.3ML IM- | 14 | 5 | 8 |
| AMLODIPINE BESYLATE (NORVASC)10MG TAB | 1,148 | 323 | 612 | CIPRODEX 0.3%-0.1% OTIC DROPS SUSP | 194 | 79 | 128 |
| TRIUMEQ 600/50/300 MG TABLET | 501 | 203 | 330 | METHYLPHENIDATE (CONCERTA)18MG TAB ER 24 | 457 | 217 | 332 |
| PRECISION XTRA BLOOD GLUCOSE TEST STRIPS | 7,227 | 1,944 | 3,767 | VENLAFAXINE XR (EFFEXOR XR) 150MG CPSR | 473 | 199 | 318 |
| ISOTRETINOIN (ACCUTANE) 40MG CAP | 726 | 240 | 423 | LORATADINE (CLARITIN) 10MG TAB--PO 10MG | 2,623 | 616 | 1,278 |
| SERTRALINE (ZOLOFT) 100MG ORAL TABLET--P | 1,590 | 468 | 868 | CLINDAMYCIN (CLEOCIN) 150MG CAP--PO 150M | 1,815 | 624 | 1,082 |
| ONDANSETRON HCL (ZOFRAN) 4 MG ORAL TAB | 624 | 149 | 306 | METFORMIN HCL 500 MG ORAL TABLET | 3,253 | 1,048 | 1,868 |
| HYDROCODONE/ACETAMINOPHEN 5MG-325MG TAB | 5,176 | 763 | 2,068 | METHYLPHENIDATE 54MG TAB ER 24--PO 54MG | 342 | 166 | 252 |
| ORTHO-CYCLEN (0.25-0.035) 28 COUNT TAB | 569 | 342 | 486 | MELOXICAM (MOBIC) 7.5MG ORAL TABLET | 792 | 300 | 499 |
| ADALIMUMAB(HUMIRA)40MG/0.8ML SQ PEN | 42 | 16 | 27 | MINOCYCLINE HCL 100 MG ORAL CAPSULE--PO | 596 | 249 | 399 |
| HARVONI 90/400MG ORAL TAB | 25 | 22 | 28 | POLYETHYLENE GLYCOL 3350(SMOOTHLAX)17G/D | 37,804 | 7,332 | 16,864 |
| COMPLERA 200-25-300MG TABLET | 254 | 145 | 209 | SODIUM FLUORIDE1.1%(PREVIDENT 5000 PLUS) | 320 | 298 | 379 |
| FLUOXETINE (PROZAC) PO 20MG CAP--PO 20MG | 1,367 | 478 | 822 | SERTRALINE (ZOLOFT) 25MG ORAL TABLET--PO | 465 | 195 | 312 |
| OXYCODONE/ACETAMIN(PERCOCET) 5/325MG TAB | 7,539 | 1,262 | 3,163 | GABAPENTIN (NEURONTIN) 100MG CAP--PO 100 | 1,061 | 428 | 695 |
| ONDANSETRON HCL (ZOFRAN) 8 MG ORAL TAB | 337 | 130 | 215 | PIMECROLIMUS (ELIDEL) 1% CREAM--TOP 1% C | 537 | 247 | 382 |
| FLUTICASONE (FLOVENT HFA) 110 MCG INH | 369 | 146 | 239 | OXYCODONE HCL(OXYCONTIN) 10 MG ER TAB | 705 | 180 | 357 |
| CLINDAMYCIN (CLEOCIN) TOP 1% GEL | 199 | 112 | 163 | LOSARTAN POTASSIUM (COZAAR) 50MG TABLET | 731 | 269 | 453 |
| ATRIPLA (EFAV/EMTRIC/TENOF 600-200-300) | 162 | 107 | 148 | ESOMEPRAZOLE (NEXIUM) 20MG PO CAP--PO 20 | 1,846 | 533 | 999 |
| ISOTRETINOIN (ACCUTANE) 10MG CAPSULE | 440 | 172 | 283 | CITALOPRAM(CELEXA) 20MG TAB--PO 20MG TAB | 515 | 207 | 337 |
| RANITIDINE HCL (ZANTAC) 150MG TAB | 5,310 | 1,029 | 2,368 | CYCLOBENZAPRINE (FLEXERIL) 10MG TAB | 1,533 | 382 | 769 |
| LIDODERM 5% PATCH (LIDOCAINE) | 1,501 | 343 | 721 | TRETINOIN (RETIN-A MICRO) 0.04% GEL | 401 | 150 | 251 |
| TAMSULOSIN (FLOMAX EQ) 0.4MG PO CAP | 1,746 | 453 | 894 | BACLOFEN (LIORESAL) 10MG TAB--PO 10MG TA | 647 | 355 | 518 |
| STRIBILD 150/150/200/300MG TABLET | 138 | 96 | 131 | HYDROXYZINE (ATARAX) 25MG ORAL TAB | 1,748 | 530 | 971 |
| VENLAFAXINE XR (EFFEXOR XR) 75MG CAP | 473 | 199 | 318 | ACYCLOVIR 400 MG ORAL TABLET--PO 400MG T | 831 | 358 | 567 |
| AZITHROMYCIN (ZITHROMAX) Z-PAK 5 DAY REG | 95 | 28 | 52 | SILDENAFIL (VIAGRA) 100MG ORAL TABLET | 417 | 115 | 220 |
| CIPROFLOXACIN (CIPRO) 500MG TAB--PO 500M | 1,038 | 152 | 414 | PREDNISOLONE (PRED FORTE)-OPT 1% SUSP | 135 | 42 | 76 |
| DOLUTEGRAVIR(TIVICAY) 50MG PO TAB | 192 | 129 | 178 | LISINOPRIL 10MG ORAL TABLET | 1,536 | 440 | 828 |
| FREESTYLE LITE TEST STRIPS | 3,140 | 1,082 | 1,874 | ESTRADIOL(VIVELLE-DOT)0.1MG/24HR TDRM--T | 227 | 79 | 137 |
| OXYCODONE (OXYCONTIN) 20MG SR TAB | 370 | 195 | 288 | OXYCODONE HCL/ACETAMINOPHEN 5-325MG TAB | 944 | 309 | 547 |
| GABAPENTIN (NEURONTIN) 300MG CAP--PO 300 | 3,595 | 1,017 | 1,923 | ACYCLOVIR 800 MG ORAL TABLET--PO 800MG T | 409 | 177 | 281 |
| METFORMIN HCL 1000 MG ORAL TABLET--PO 1, | 2,931 | 881 | 1,620 | TESTOSTERONE(FORTESTA)10MG PER ACTUATION | 20 | 11 | 16 |
| VALACYCLOVIR (VALTREX) 1000 MG ORAL TAB | 355 | 121 | 211 | TACROLIMUS (PROGRAF) 1MG CAP | 551 | 378 | 517 |
| LEVOFLOXACIN 750MG ORAL TABLET | 116 | 44 | 73 | MIRTAZAPINE (REMERON) 15 MG ORAL TABLET | 386 | 172 | 269 |
| DULOXETINE HCL (CYMBALTA) 60 MG PO CAP | 752 | 276 | 466 | CETIRIZINE (ZYRTEC) 10MG TAB--PO 10MG TA | 4,799 | 1,043 | 2,253 |
| MYCOPHENOLATE MOFETIL(CELLCEPT)500MG TAB | 513 | 328 | 457 | SITAGLIPTIN (JANUVIA) 100MG ORAL TAB | 614 | 237 | 392 |
| AZITHROMYCIN (ZITHROMAX) 250MG TAB--PO 2 | 120 | 50 | 81 | BUPROPION SR 150MG (WELLBUTRIN SR) TAB-- | 557 | 250 | 391 |
| APIXABAN(ELIQUIS)5MG ORAL TAB--PO 5MG TA | 1,586 | 492 | 892 | MUPIROCIN (BACTROBAN) 2 % TOPICAL OINT. | 506 | 116 | 244 |
| RIVAROXABAN (XARELTO) 20 MG ORAL TABLET | 741 | 262 | 449 | SIMVASTATIN (ZOCOR) 10MG TAB--PO 10MG TA | 489 | 183 | 307 |
| METHYLPHENIDATE 36MG TAB ER 24--PO 36MG | 607 | 247 | 400 | LEVETIRACETAM (KEPPRA) 500MG ORAL TAB | 743 | 351 | 538 |
| AMLODIPINE BESYLATE (NORVASC)5MG TAB--PO | 1,470 | 437 | 808 | FENTANYL (DURAGESIC) TDRM* 100MCG/HR TDS | 22 | 20 | 26 |
| SIMVASTATIN (ZOCOR) 40MG ORAL TABLET | 792 | 277 | 477 | TIZANIDINE (ZANAFLEX) 4MG TAB | 799 | 311 | 513 |
| DOXYLAMINE/PYRIDOXINE(DICLEGIS)10/10MG-- | 925 | 290 | 523 | COLCHICINE 0.6MG TABLET | 692 | 257 | 431 |
| LEVOFLOXACIN 500MG ORAL TAB | 79 | 35 | 55 | BUPROPION XL (WELLBUTRIN XL) 300MG TAB-- | 651 | 249 | 413 |
| METRONIDAZOLE 500 MG ORAL TABLET | 550 | 117 | 255 | BENZONATATE (TESSALON) 100MG CAP--PO 100 | 1,280 | 372 | 695 |
| ETONOGESTREL/ETHINYL ESTRADIOL(NUVARING) | 48 | 18 | 30 | DOCUSATE CALCIUM (SURFAK) 240MG PO CAP | 12,418 | 2,512 | 5,644 |
| TRAMADOL (ULTRAM) 50MG ORAL TABLET--PO 5 | 3,597 | 819 | 1,726 | OXYCODONE (ROXICODONE) 15MG/ML PO SOLN | 889 | 438 | 662 |
| ESOMEPRAZOLE (NEXIUM) 40MG PO CAP--PO 40 | 3,030 | 751 | 1,515 | DEXTROAMPHETAMINE/AMPHETAM 20MG XR CAP-- | 870 | 311 | 530 |
| PREGABALIN (LYRICA) 75MG CAP--PO 75MG CA | 977 | 380 | 626 | METOPROLOL SUCCINATE 100MG (TOPROL XL)-- | 576 | 212 | 357 |

Table 17. Continuous Review, AE Medication Results. Adapted from Chopra & Meindl, (2013), Krajewski & Ritzman, (1996).

| | n* | 64.6 | | | Service Level | 90% |
|---|---|---|---|---|---|---|
| **Medication Name** | **JOQ** | **Safety Stock** | **Reorder Point** | **Medication Name** | **JOQ** | **Safety Stock** | **ROP** |
| ATOMOXETINE (STRATTERA) 40MG CAP | 210 | 88 | 125 | FOLLISTIM AQ 600 U/0.72ML CARTRIDGE SQ-- | 13 | 3 | 5 |
| CLINDAMYCIN (CLEOCIN-T) 1% TOP SOLN | 281 | 126 | 176 | ENOXAPARIN (LOVENOX) 80MG/.8ML SQ UI/SYR | 89 | 32 | 48 |
| CEPHALEXIN 250MG/5ML SUSP 200ML--PO 250M | 1,064 | 330 | 518 | TADALAFIL 20MG (CIALIS) TAB--PO 20MG TAB | 128 | 30 | 53 |
| PEGFILGRASTIM (NEULASTA) 6MG/0.6ML SYR | 9 | 2 | 3 | GOSERELIN ACET (ZOLADEX) 10.8MG DEPOT | 7 | 2 | 3 |
| THYROTROPIN ALFA(THYROGEN)1.1MG IM INJ | 4 | 2 | 2 | IPRATROPIUM INHALER *HFA* 12.9GM--INH 17 | 45 | 21 | 29 |
| VANICREAM TOPICAL CREAM *OTC*--TOP CREA | 1,413 | 683 | 932 | DULOXETINE HCL (CYMBALTA) 20 MG PO CAP-- | 544 | 158 | 254 |
| ONABOTULINUMTOXINA(BOTOX)200UNIT IN VIAL | 23 | 7 | 11 | FLUTICASONE/SALMETEROL 230-21MCG HFA INH | 69 | 28 | 41 |
| MESALAMINE (LIALDA) 1.2GM ORAL TABLET DR | 1,807 | 443 | 762 | DESONIDE (DESOWEN) 0.05 % TOPICAL CREAM- | 262 | 114 | 161 |
| MOMETASONE FUROATE (NASONEX) 50MCG NASAL | 127 | 49 | 71 | FILGRASTIM (G-CSF) 300MCG/0.5ML SYRN | 12 | 6 | 9 |
| GABAPENTIN (NEURONTIN) 600MG TAB | 1,144 | 317 | 519 | PREGABALIN (LYRICA) 150MG CAP--PO 150MG | 891 | 235 | 392 |
| ONABOTULINUMTOXINA(BOTOX)100UNIT IN VIAL | 21 | 6 | 10 | AZATHIOPRINE (IMURAN) 50MG ORAL TAB--PO | 717 | 239 | 365 |
| DIATRIZ MEGLU/DIATRI NA(GASTROGRAFIN) | 7 | 11 | 13 | SUMATRIPTAN (IMITREX) 6MG/.5ML SQ CARTG | 19 | 10 | 14 |
| TEMOZOLOMIDE (TEMODAR) 100MG CAP | 27 | 13 | 17 | KETOCONAZOLE (NIZORAL) TOP 2% CREAM | 530 | 120 | 214 |
| CLOBETASOL (OLUX) 0.05% FOAM 100GM | 883 | 252 | 408 | LAMOTRIGINE (LAMICTAL) 25MG ORAL TAB | 555 | 163 | 261 |
| FLUTICASONE(FLOVENT HFA) 220 MCG INH | 150 | 45 | 71 | LANSOPRAZOLE(PREVACID)15MG SOLUTAB | 392 | 143 | 212 |
| FILGRASTIM (G-CSF) 480MCG/0.8ML SYRN | 12 | 6 | 8 | ORTHO TRI-CYCLEN LO 28 DAY ORAL TABLETS | 840 | 243 | 391 |
| RALTEGRAVIR POTAS(ISENTRESS)400MG TAB | 413 | 136 | 209 | CALCIP/BETA(TACLONEX)0.005-0.064TOP SUSP | 278 | 118 | 167 |
| ENTECAVIR (BARACLUDE) 0.5MG ORAL TAB | 167 | 75 | 104 | MIRABEGRON(MYRBETRIQ) 25MG ER 24HR TAB | 656 | 182 | 297 |
| VANCOMYCIN (VANCOCIN) 125MG ORAL CAP | 147 | 47 | 73 | VENLAFAXINE XR (EFFEXOR XR) 37.5MG CAP | 466 | 131 | 213 |
| TENOFOVIR DISOPROXIL (VIREAD) 300 MG TAB | 249 | 83 | 127 | EPINEPHRINE(EPIPEN JR 2-PAK)0.15MG/0.3ML | 11 | 3 | 5 |
| CLOBETASOL (TEMOVATE)--TOP 0.05% OINT | 555 | 395 | 493 | MONTELUKAST SODIUM (SINGULAIR) 5MG TBCH- | 387 | 114 | 182 |
| ARIPIPRAZOLE (ABILIFY) 5MG TAB--PO 5MG T | 341 | 95 | 156 | CEFIXIME (SUPRAX) 100MG/5ML PO SUSP | 434 | 152 | 229 |
| FOLLISTIM AQ 900/1.08ML CARTRIDGE SQ--SQ | 8 | 2 | 4 | SUMATRIPTAN (IMITREX) 100MG TAB--PO 100M | 86 | 26 | 41 |
| LAMOTRIGINE (LAMICTAL) 100MG ORAL TAB | 859 | 249 | 400 | DABIGATRAN(PRADAXA) 150MG ORAL CAP | 412 | 156 | 228 |
| IMIQUIMOD (ALDARA)--TOP 5% CREA | 127 | 34 | 57 | LIDOCAINE (XYLOCAINE)--TOP 5% OINT | 348 | 105 | 167 |
| FLUCONAZOLE (DIFLUCAN) 200MG TAB--PO 200 | 205 | 90 | 126 | NALTREXONE MICROSPHERES (VIVITROL)380MG | 2 | 1 | 1 |
| FLUOXETINE (PROZAC) PO 10MG CAP--PO 10MG | 515 | 142 | 233 | DONEPEZIL HCL (ARICEPT) 10 MG ORAL TAB-- | 203 | 76 | 112 |
| SITAGLIPTIN (JANUVIA) 25MG ORAL TABLET | 237 | 97 | 139 | ENOXAPARIN (LOVENOX) 40MG/0.4ML SQ SYR-- | 170 | 45 | 75 |
| SYRINGE 23GX1IN 3ML WITH NEEDLE | 67 | 37 | 49 | MESALAMINE(CANASA) 1000MG RECTAL SUPP | 131 | 63 | 86 |
| TACLONEX(CALCIPO/BETAMET).005/.064% OINT | 437 | 168 | 245 | SEVELAMER (RENVELA) 800MG PO TAB | 1,452 | 533 | 790 |
| CAPECITABINE (XELODA) 500MG TAB--PO 500M | 389 | 121 | 189 | RABEPRAZOLE (ACIPHEX) 20MG ORAL TAB | 213 | 93 | 131 |
| CLOBAZAM (ONFI) 2.5MG/ML ORAL SUSPENSION | 1,255 | 544 | 765 | PREGABALIN (LYRICA) 100MG CAP--PO 100MG | 587 | 207 | 311 |
| TOPIRAMATE (TOPAMAX) 100MG TAB | 510 | 151 | 241 | AMLODIPINE BESYLATE (NORVASC)2.5MG TAB-- | 694 | 168 | 290 |
| CABERGOLINE (DOSTINEX) 0.5MG TABLET | 97 | 40 | 57 | ONABOTULINUMTOXINA (BOTOX COSMETIC) 50U | 4 | 2 | 2 |
| RIFAXIMIN (XIFAXAN) 550 MG ORAL TABLET | 311 | 123 | 178 | RISPERIDONE (RISPERDAL) 1MG ORAL TAB | 305 | 172 | 226 |
| ADAPALENE 0.1 % TOPICAL CREAM | 96 | 43 | 60 | VARDENAFIL 20MG TAB (LEVITRA) | 84 | 25 | 40 |
| ARIPIPRAZOLE (ABILIFY) 2MG ORAL TAB | 257 | 76 | 121 | BUMETANIDE (BUMEX) 1MG TAB | 1,207 | 333 | 546 |
| SUMATRIPTAN (IMITREX) 50MG TAB--PO 50MG | 155 | 42 | 69 | SITAGLIP/METFORM(JANUMET) 50-1000MG TAB | 1,402 | 330 | 577 |
| TADALAFIL (CIALIS) 5MG TAB | 805 | 196 | 338 | CLINDAMYCIN/BENZOYL (DUAC)1.2(1)%-5% TOP | 319 | 84 | 141 |
| MENOTROPINS (MENOPUR) 75 UNIT SUB-Q VIAL | 72 | 20 | 32 | TIOTROPIUM (SPIRIVA) 18MCG/CAP INH PWDR- | 561 | 132 | 231 |
| FLUTICASONE/SALMETEROL 115-21MCG HFA INH | 101 | 39 | 57 | CYCLOSPORINE (RESTASIS) 0.05% OPTH SOLN- | 640 | 192 | 306 |

36

Table 18. Continuous Review, AN Medication Results. Adapted from Chopra & Meindl, (2013), Krajewski & Ritzman, (1996).

| | n* | 75.4 | | | Service Level | 95% | |
|---|---|---|---|---|---|---|---|
| Medication Name | JOQ | Safety Stock | Reorder Point | Medication Name | JOQ | Safety Stock | ROP |
| TRUVADA 200MG/300MG ORAL TAB | 948 | 327 | 566 | DERMA-SMOOTHE/FS OIL-FLUOCINOLONE 0.01%- | 1,435 | 599 | 961 |
| FLUTICASONE (FLONASE) 50MCG NAS INH 16GM | 514 | 248 | 378 | ZOLPIDEM TARTRATE (AMBIEN) 5 MG ORAL TAB | 633 | 196 | 356 |
| LANTUS SOLOSTAR 300U/3ML PREFILLED PEN | 600 | 238 | 389 | MOXIFLOXACIN HCL (VIGAMOX) 0.5 % OPHTHAL | 123 | 177 | 207 |
| RIZATRIPTAN (MAXALT) 10MG ORAL TABLET | 50 | 38 | 51 | EPINEPHRINE(EPIPEN 2-PAK)0.3MG/0.3ML IM- | 14 | 5 | 8 |
| AMLODIPINE BESYLATE (NORVASC)10MG TAB | 1,148 | 323 | 612 | CIPRODEX 0.3%-0.1% OTIC DROPS SUSP | 194 | 79 | 128 |
| TRIUMEQ 600/50/300 MG TABLET | 501 | 203 | 330 | METHYLPHENIDATE (CONCERTA)18MG TAB ER 24 | 457 | 217 | 332 |
| PRECISION XTRA BLOOD GLUCOSE TEST STRIPS | 7,227 | 1,944 | 3,767 | VENLAFAXINE XR (EFFEXOR XR) 150MG CPSR | 473 | 199 | 318 |
| ISOTRETINOIN (ACCUTANE) 40MG CAP | 726 | 240 | 423 | LORATADINE (CLARITIN) 10MG TAB--PO 10MG | 2,623 | 616 | 1,278 |
| SERTRALINE (ZOLOFT) 100MG ORAL TABLET--P | 1,590 | 468 | 868 | CLINDAMYCIN (CLEOCIN) 150MG CAP--PO 150M | 1,815 | 624 | 1,082 |
| ONDANSETRON HCL (ZOFRAN) 4 MG ORAL TAB | 624 | 149 | 306 | METFORMIN HCL 500 MG ORAL TABLET | 3,253 | 1,048 | 1,868 |
| HYDROCODONE/ACETAMINOPHEN 5MG-325MG TAB | 5,176 | 763 | 2,068 | METHYLPHENIDATE 54MG TAB ER 24--PO 54MG | 342 | 166 | 252 |
| ORTHO-CYCLEN (0.25-0.035) 28 COUNT TAB | 569 | 342 | 486 | MELOXICAM (MOBIC) 7.5MG ORAL TABLET | 792 | 300 | 499 |
| ADALIMUMAB(HUMIRA)40MG/0.8ML SQ PEN | 42 | 16 | 27 | MINOCYCLINE HCL 100 MG ORAL CAPSULE--PO | 596 | 249 | 399 |
| HARVONI 90/400MG ORAL TAB | 25 | 22 | 28 | POLYETHYLENE GLYCOL 3350(SMOOTHLAX)17G/D | 37,804 | 7,332 | 16,864 |
| COMPLERA 200-25-300MG TABLET | 254 | 145 | 209 | SODIUM FLUORIDE1.1%(PREVIDENT 5000 PLUS) | 320 | 298 | 379 |
| FLUOXETINE (PROZAC) PO 20MG CAP--PO 20MG | 1,367 | 478 | 822 | SERTRALINE (ZOLOFT) 25MG ORAL TABLET--PO | 465 | 195 | 312 |
| OXYCODONE/ACETAMIN(PERCOCET) 5/325MG TAB | 7,539 | 1,262 | 3,163 | GABAPENTIN (NEURONTIN) 100MG CAP--PO 100 | 1,061 | 428 | 695 |
| ONDANSETRON HCL (ZOFRAN) 8 MG ORAL TAB | 337 | 130 | 215 | PIMECROLIMUS (ELIDEL) 1% CREAM--TOP 1% C | 537 | 247 | 382 |
| FLUTICASONE (FLOVENT HFA) 110 MCG INH | 369 | 146 | 239 | OXYCODONE HCL(OXYCONTIN) 10 MG ER TAB | 705 | 180 | 357 |
| CLINDAMYCIN (CLEOCIN) TOP 1% GEL | 199 | 112 | 163 | LOSARTAN POTASSIUM (COZAAR) 50MG TABLET | 731 | 269 | 453 |
| ATRIPLA (EFAV/EMTRIC/TENOF 600-200-300) | 162 | 107 | 148 | ESOMEPRAZOLE (NEXIUM) 20MG PO CAP--PO 20 | 1,846 | 533 | 999 |
| ISOTRETINOIN (ACCUTANE) 10MG CAPSULE | 440 | 172 | 283 | CITALOPRAM(CELEXA) 20MG TAB--PO 20MG TAB | 515 | 207 | 337 |
| RANITIDINE HCL (ZANTAC) 150MG TAB | 5,310 | 1,029 | 2,368 | CYCLOBENZAPRINE (FLEXERIL) 10MG TAB | 1,533 | 382 | 769 |
| LIDODERM 5% PATCH (LIDOCAINE) | 1,501 | 343 | 721 | TRETINOIN (RETIN-A MICRO) 0.04% GEL | 401 | 150 | 251 |
| TAMSULOSIN (FLOMAX EQ) 0.4MG PO CAP | 1,746 | 453 | 894 | BACLOFEN (LIORESAL) 10MG TAB--PO 10MG TA | 647 | 355 | 518 |
| STRIBILD 150/150/200/300MG TABLET | 138 | 96 | 131 | HYDROXYZINE HCL (ATARAX) 25MG ORAL TAB | 1,748 | 530 | 971 |
| VENLAFAXINE XR (EFFEXOR XR) 75MG CAP | 473 | 199 | 318 | ACYCLOVIR 400 MG ORAL TABLET--PO 400MG T | 831 | 358 | 567 |
| AZITHROMYCIN (ZITHROMAX) Z-PAK 5 DAY REG | 95 | 28 | 52 | SILDENAFIL (VIAGRA) 100MG ORAL TABLET | 417 | 115 | 220 |
| CIPROFLOXACIN (CIPRO) 500MG TAB--PO 500M | 1,038 | 152 | 414 | PREDNISOLONE (PRED FORTE)-OPT 1% SUSP | 135 | 42 | 76 |
| DOLUTEGRAVIR(TIVICAY) 50MG PO TAB | 192 | 129 | 178 | LISINOPRIL 10MG ORAL TABLET | 1,536 | 440 | 828 |
| FREESTYLE LITE TEST STRIPS | 3,140 | 1,082 | 1,874 | ESTRADIOL(VIVELLE-DOT)0.1MG/24HR TDRM--T | 227 | 79 | 137 |
| OXYCODONE (OXYCONTIN) 20MG SR TAB | 370 | 195 | 288 | OXYCODONE HCL/ACETAMINOPHEN 5-325MG TAB | 944 | 309 | 547 |
| GABAPENTIN (NEURONTIN) 300MG CAP--PO 300 | 3,595 | 1,017 | 1,923 | ACYCLOVIR 800 MG ORAL TABLET--PO 800MG T | 409 | 177 | 281 |
| METFORMIN HCL 1000 MG ORAL TABLET--PO 1, | 2,931 | 881 | 1,620 | TESTOSTERONE(FORTESTA)10MG PER ACTUATION | 20 | 11 | 16 |
| VALACYCLOVIR (VALTREX) 1000 MG ORAL TAB | 355 | 121 | 211 | TACROLIMUS (PROGRAF) 1MG CAP | 551 | 378 | 517 |
| LEVOFLOXACIN 750MG ORAL TABLET | 116 | 44 | 73 | MIRTAZAPINE (REMERON) 15 MG ORAL TABLET | 386 | 172 | 269 |
| DULOXETINE HCL (CYMBALTA) 60 MG PO CAP | 752 | 276 | 466 | CETIRIZINE (ZYRTEC) 10MG TAB--PO 10MG TA | 4,799 | 1,043 | 2,253 |
| MYCOPHENOLATE MOFETIL(CELLCEPT)500MG TAB | 513 | 328 | 457 | SITAGLIPTIN (JANUVIA) 100MG ORAL TAB | 614 | 237 | 392 |
| AZITHROMYCIN (ZITHROMAX) 250MG TAB--PO 2 | 120 | 50 | 81 | BUPROPION SR 150MG (WELLBUTRIN SR) TAB-- | 557 | 250 | 391 |
| APIXABAN(ELIQUIS)5MG ORAL TAB--PO 5MG TA | 1,586 | 492 | 892 | MUPIROCIN (BACTROBAN) 2 % TOPICAL OINT. | 506 | 116 | 244 |
| RIVAROXABAN (XARELTO) 20 MG ORAL TABLET | 741 | 262 | 449 | SIMVASTATIN (ZOCOR) 10MG TAB--PO 10MG TA | 489 | 183 | 307 |
| METHYLPHENIDATE 36MG TAB ER 24--PO 36MG | 607 | 247 | 400 | LEVETIRACETAM (KEPPRA) 500MG ORAL TAB | 743 | 351 | 538 |
| AMLODIPINE BESYLATE (NORVASC)5MG TAB--PO | 1,470 | 437 | 808 | FENTANYL (DURAGESIC) TDRM* 100MCG/HR TDS | 22 | 20 | 26 |
| SIMVASTATIN (ZOCOR) 40MG ORAL TABLET | 792 | 277 | 477 | TIZANIDINE (ZANAFLEX) 4MG TAB | 799 | 311 | 513 |
| DOXYLAMINE/PYRIDOXINE(DICLEGIS)10/10MG-- | 925 | 290 | 523 | COLCHICINE 0.6MG TABLET | 692 | 257 | 431 |
| LEVOFLOXACIN 500MG ORAL TAB | 79 | 35 | 55 | BUPROPION XL (WELLBUTRIN XL) 300MG TAB-- | 651 | 249 | 413 |
| METRONIDAZOLE 500 MG ORAL TABLET | 550 | 117 | 255 | BENZONATATE (TESSALON) 100MG CAP--PO 100 | 1,280 | 372 | 695 |
| ETONOGESTREL/ETHINYL ESTRADIOL(NUVARING) | 48 | 18 | 30 | DOCUSATE CALCIUM (SURFAK) 240MG PO CAP | 12,418 | 2,512 | 5,644 |
| TRAMADOL (ULTRAM) 50MG ORAL TABLET--PO 5 | 3,597 | 819 | 1,726 | OXYCODONE (ROXICODONE) 1MG/ML PO SOLN | 889 | 438 | 662 |
| ESOMEPRAZOLE (NEXIUM) 40MG PO CAP--PO 40 | 3,030 | 751 | 1,515 | DEXTROAMPHETAMINE/AMPHETAM 20MG XR CAP-- | 870 | 311 | 530 |
| PREGABALIN (LYRICA) 75MG CAP--PO 75MG CA | 977 | 380 | 626 | METOPROLOL SUCCINATE 100MG (TOPROL XL)-- | 576 | 212 | 357 |

Table 19.    Continuous Review, BV Medication Results.  Adapted from Chopra & Meindl, (2013), Krajewski & Ritzman, (1996).

| | n* | 26.8 | | | Service Level | 95% |
|---|---|---|---|---|---|---|

| Medication Name | JOQ | Safety Stock | Reorder Point | Medication Name | JOQ | Safety Stock | ROP |
|---|---|---|---|---|---|---|---|
| NORELGESTROMIN/ETHIN.ESTRADIOL PATCH--TD | 188 | 22 | 36 | ALPRAZOLAM 0.5 MG ORAL TABLET | 1947 | 284 | 427 |
| ALBUTEROL SULFA(PROAIR HFA)90MCG INH HFA | 432 | 30 | 61 | WARFARIN SODIUM 5MG TABLET (GENERIC) | 6183 | 635 | 1087 |
| AUGMENTIN XR AMOX/POT 1000-62.5MG TAB--P | 984 | 107 | 179 | PSEUDOEPHEDRINE (SUDAFED) 30MG TAB *OTC* | 3784 | 260 | 537 |
| HYDROCODONE/ACETAMINOPHEN 10MG-325MG TA | 3754 | 338 | 612 | IBUPROFEN(ADVIL)100MG/5ML PO SUSP OTC--P | 34797 | 1664 | 4211 |
| MOXIFLOXACIN HCL (AVELOX) 400MG ORAL TAB | 423 | 47 | 78 | AMOXICILLIN/K CLAVULANATE 500-125MG TAB- | 430 | 47 | 78 |
| BUSPIRONE (BUSPAR) PO 10MG TAB--PO 10MG | 2787 | 400 | 604 | FENTANYL (DURAGESIC) TDRM 25MCG/HR TDSY- | 96 | 28 | 35 |
| INSULIN ASPART (NOVOLOG FLEXPEN) 100/ML- | 1745 | 568 | 696 | GUAIFENESIN LA (MUCINEX) PO 600MG TBSR-- | 2319 | 199 | 369 |
| AZITHROMYCIN (TRI-PAK) 500MG TAB | 159 | 25 | 36 | NITROFURANTOIN MONO-MACRO(MACROBID)100 | 2497 | 165 | 348 |
| TRAZODONE (DESYREL TYPE) 50MG TABLET--PO | 4404 | 396 | 719 | OLOPATADINE HCL(PATADAY) 0.2% OPHTH DROP | 109 | 12 | 20 |
| METHYLPHENIDATE 27MG TAB ER 24--PO 27MG | 1680 | 219 | 342 | PROCTOFOAM-HC (EQUIV) RECT FOAM--RECT 1% | 259 | 34 | 52 |
| TELMISARTAN (MICARDIS) 40MG TAB--PO 40MG | 2293 | 255 | 423 | COTRIMOXAZOLE (SEPTRA) 40MG/5ML PO SUSP- | 6078 | 732 | 1177 |
| TELMISARTAN (MICARDIS) 80MG TAB--PO 80MG | 2179 | 217 | 377 | IBUPROFEN (MOTRIN) 800MG ORAL TABLET--PO | 38643 | 1461 | 4290 |
| CLOMIPHENE (CLOMID) PO 50MG TABLET--PO 5 | 395 | 48 | 77 | CO-TRIMOXAZOLE(SEPTRA DS) 800/160MG TAB- | 1218 | 146 | 235 |
| TRAZODONE (DESYREL TYPE) 100MG TABLET--P | 2038 | 254 | 403 | REFRESH TEARS 0.5% OPHT DROP | 3110 | 235 | 462 |
| HYDROCODONE/CHLORPH(TUSSIONEX)10-8MG/5ML | 4636 | 499 | 839 | OMEPRAZOLE 20 MG ORAL CAPSULE DR--PO 20M | 16648 | 1040 | 2259 |
| METFORMIN HCL (GLUCOPHAGE XR) 500MG TAB- | 3928 | 476 | 763 | PHENAZOPYRIDINE HCL 100 MG ORAL TABLET | 1287 | 71 | 165 |
| EE/DROSPIRENONE (YAZ) 0.02-3 MG ORAL TAB | 3572 | 451 | 712 | TESTOSTERONE CYPIONATE 200MG/ML INJ  1ML | 202 | 25 | 40 |
| DEXTROAMPHETAMINE/AMPHETAM 30MG XR CAP-- | 2304 | 260 | 428 | AMOXICILLIN 250MG/5ML ORAL SUSP | 19995 | 1428 | 2892 |
| FLUTICASONE/SALMETEROL 250-50MCG INH DSK | 99 | 23 | 30 | ESCITALOPRAM 10MG (LEXAPRO) TAB | 2313 | 247 | 417 |
| LISINOPRIL 5MG ORAL TABLET | 2998 | 281 | 501 | CLONAZEPAM (KLONOPIN) PO 0.5MG TAB--PO 0 | 1780 | 235 | 365 |
| FLUCONAZOLE (DIFLUCAN) 150MG TAB--PO 150 | 142 | 17 | 27 | FOLIC ACID (FOLATE) 1MG TAB--PO 1MG TAB | 3696 | 371 | 641 |
| MECLIZINE HCL (ANTIVERT) 25 MG ORAL TAB- | 1928 | 178 | 319 | CETIRIZINE (ZYRTEC) 5MG/5ML PO SOLN--PO | 13314 | 1215 | 2190 |
| METOPROLOL SUCCINATE 50MG (TOPROL XL) | 3336 | 341 | 585 | AZITHROMYCIN (ZITHROMAX) 1GM PACK | 27 | 3 | 5 |
| CHORIONIC GONADOTROPIN(OVIDREL)250MCG SQ | 44 | 4 | 7 | ALLOPURINOL 100 MG ORAL TABLET--PO 100MG | 2943 | 332 | 548 |
| LANTUS INSULIN 100U/ML INJ | 857 | 108 | 171 | BUPROPION XL (WELLBUTRIN XL)150MG TAB--P | 2892 | 321 | 532 |
| OXYCODONE 5MG IR TAB ORAL--PO 5MG TAB | 11642 | 757 | 1609 | PROMETHAZINE HCL 25MG ORAL TABLET | 2496 | 180 | 363 |
| KETOCONAZOLE--TOP 2% SHAM | 7419 | 746 | 1289 | CELLUVISC 1% OPT DROP *OTC*--OPT AMP | 4119 | 311 | 612 |
| ONDANSETRON (ZOFRAN ODT) 4 MG TAB RAPDIS | 6318 | 260 | 723 | BENZOCAINE/MENTHOL (CEPACOL SORE THROAT) | 367 | 35 | 62 |
| FENTANYL (DURAGESIC) TDRM 50MCG/HR TDSY- | 79 | 18 | 24 | PANTOPRAZOLE SODIUM 40 MG ORAL TABLET DR | 2664 | 285 | 480 |
| METHOTREXATE NA(METHOTREXATE)2.5MG TAB | 1331 | 169 | 266 | AZITHROMYCIN(ZITHROMAX)200MG/5ML PO SUSP | 816 | 215 | 275 |
| CELECOXIB (CELEBREX) PO 200MG CAP--PO 20 | 3160 | 287 | 518 | WARFARIN SODIUM 2.5MG (GENERIC) TAB | 4327 | 469 | 786 |
| SILDENAFIL (VIAGRA) 50MG ORAL TABLET | 562 | 61 | 102 | MORPHINE (MS CONTIN) 30MG TBSR--PO 30MG | 370 | 80 | 107 |
| DEXTROAMPHETAMINE/AMPHETAM 10MG XR CAP-- | 1618 | 197 | 315 | ATORVASTATIN (LIPITOR) 80MG TAB | 5066 | 396 | 767 |
| OXYCODONE (OXYCONTIN) 40MG SR TAB | 434 | 86 | 118 | NAPROXEN (NAPROSYN) 500 MG ORAL TABLET | 18915 | 921 | 2306 |
| INSULIN ASPART (NOVOLOG) 100U/ML SUB-Q-- | 991 | 124 | 197 | NORETHINDRONE-E.ES-IRON 1MG-20(28) TAB | 2429 | 313 | 491 |
| FENTANYL (DURAGESIC) TDRM 75MCG/HR TDSY- | 42 | 11 | 14 | ALFUZOSIN HCL (UROXATRAL) 10MG ER TAB--P | 2194 | 250 | 411 |
| ATENOLOL 50 MG TAB | 2442 | 266 | 445 | GUAIFENESIN/CODEINE100-10MG/5ML ORAL SYR | 18573 | 1638 | 2998 |
| ASPIRIN (ASPIRIN EC) 81 MG ORAL TABLET-- | 42216 | 3111 | 6202 | NEEDLES INSULIN(SURE COMFORT)32GX0.25 IN | 7648 | 822 | 1382 |
| NORETHINDRONE (NOR-Q-D) 0.35 MG ORAL TAB | 6446 | 412 | 884 | CHOLECALCIFEROL(VITAMIN D3/D)400IU/ML PO | 7854 | 1676 | 2251 |
| OMEPRAZOLE (FIRST-OMEPRAZOLE) 2 MG/ML | 5520 | 656 | 1060 | LUBRICANT EYE DROPS (GENTEAL) *OTC* | 1663 | 174 | 296 |
| ELECTROLYTE MIXTURE (CO-LYTE GOLYTELY) | 458 | 490 | 524 | CLOTRIMAZOLE (MYCELEX) 1% CRM *OTC*--TOP | 1422 | 132 | 236 |
| ACETAMINOPHEN(MAPAP)160MG/5MLORAL ELIXIR | 40617 | 1856 | 4830 | PROGESTERONE IN OIL 50MG/ML VIAL*NF* | 758 | 78 | 133 |
| CHLORHEXIDINE GLUCONATE 0.12 % MOUTHWASH | 84234 | 6076 | 12244 | LORAZEPAM (ATIVAN) PO 1MG TAB--PO 1MG TA | 1100 | 153 | 234 |
| PENICILLIN V K 500MG ORAL TABLET | 878 | 97 | 161 | OLOPATADINE HCL (PATANOL) 0.1 % OPH DROP | 107 | 14 | 21 |
| ATENOLOL 25 MG TAB | 2083 | 237 | 389 | MORPHINE (MS CONTIN) 15MG TBSR--PO 15MG | 584 | 103 | 146 |
| HYDROXYZINE HCL (ATARAX) 10MG ORAL TAB | 2549 | 314 | 501 | DIAZEPAM (VALIUM) 5MG PO TAB--PO 5MG TAB | 4269 | 351 | 664 |
| POLYMYXIN B TRIMETHOPRIM OPTH SOLN--OPT | 514 | 41 | 79 | METOPROLOL SUCCINATE 25MG (TOPROL XL) | 3169 | 305 | 537 |
| NAPROXEN (NAPROSYN) 375 MG ORAL TABLET | 1547 | 162 | 276 | LORATADINE/P-EPHED (CLARITIN-D) 12HR--PO | 1403 | 161 | 263 |

38

**Table 20.** Continuous Review, CV Medication Results. Adapted from Chopra & Meindl, (2013), Krajewski & Ritzman, (1996).

| | n* | 26.8 | | | Service Level | 95% | |
|---|---|---|---|---|---|---|---|
| Medication Name | JOQ | Safety Stock | Reorder Point | Medication Name | JOQ | Safety Stock | ROP |
| NORELGESTROMIN/ETHIN.ESTRADIOL PATCH--TD | 188 | 22 | 36 | ALPRAZOLAM 0.5 MG ORAL TABLET | 1947 | 284 | 427 |
| ALBUTEROL SULFA(PROAIR HFA)90MCG INH HFA | 432 | 30 | 61 | WARFARIN SODIUM 5MG TABLET (GENERIC) | 6183 | 635 | 1087 |
| AUGMENTIN XR AMOX/POT 1000-62.5MG TAB--P | 984 | 107 | 179 | PSEUDOEPHEDRINE (SUDAFED) 30MG TAB *OTC* | 3784 | 260 | 537 |
| HYDROCODONE/ACETAMINOPHEN 10MG-325MG TA | 3754 | 338 | 612 | IBUPROFEN(ADVIL)100MG/5ML PO SUSP OTC--P | 34797 | 1664 | 4211 |
| MOXIFLOXACIN HCL (AVELOX) 400MG ORAL TAB | 423 | 47 | 78 | AMOXICILLIN/K CLAVULANATE 500-125MG TAB- | 430 | 47 | 78 |
| BUSPIRONE (BUSPAR) PO 10MG TAB--PO 10MG | 2787 | 400 | 604 | FENTANYL (DURAGESIC) TDRM 25MCG/HR TDSY- | 96 | 28 | 35 |
| INSULIN ASPART (NOVOLOG FLEXPEN) 100/ML- | 1745 | 568 | 696 | GUAIFENESIN LA (MUCINEX) PO 600MG TBSR-- | 2319 | 199 | 369 |
| AZITHROMYCIN (TRI-PAK) 500MG TAB | 159 | 25 | 36 | NITROFURANTOIN MONO-MACRO(MACROBID)100 | 2497 | 165 | 348 |
| TRAZODONE (DESYREL TYPE) 50MG TABLET--PO | 4404 | 396 | 719 | OLOPATADINE HCL(PATADAY) 0.2% OPHTH DROP | 109 | 12 | 20 |
| METHYLPHENIDATE 27MG TAB ER 24--PO 27MG | 1680 | 219 | 342 | PROCTOFOAM-HC (EQUIV) RECT FOAM--RECT 1% | 259 | 34 | 52 |
| TELMISARTAN (MICARDIS) 40MG TAB--PO 40MG | 2293 | 255 | 423 | COTRIMOXAZOLE (SEPTRA) 40MG/5ML PO SUSP- | 6078 | 732 | 1177 |
| TELMISARTAN (MICARDIS) 80MG TAB--PO 80MG | 2179 | 217 | 377 | IBUPROFEN (MOTRIN) 800MG ORAL TABLET--PO | 38643 | 1461 | 4290 |
| CLOMIPHENE (CLOMID) PO 50MG TABLET--PO 5 | 395 | 48 | 77 | CO-TRIMOXAZOLE(SEPTRA DS) 800/160MG TAB- | 1218 | 146 | 235 |
| TRAZODONE (DESYREL TYPE) 100MG TABLET--P | 2038 | 254 | 403 | REFRESH TEARS 0.5% OPHT DROP | 3110 | 235 | 462 |
| HYDROCODONE/CHLORPH(TUSSIONEX)10-8MG/5ML | 4636 | 499 | 839 | OMEPRAZOLE 20 MG ORAL CAPSULE DR--PO 20M | 16648 | 1040 | 2259 |
| METFORMIN HCL (GLUCOPHAGE XR) 500MG TAB- | 3928 | 476 | 763 | PHENAZOPYRIDINE HCL 100 MG ORAL TABLET | 1287 | 71 | 165 |
| EE/DROSPIRENONE (YAZ) 0.02-3 MG ORAL TAB | 3572 | 451 | 712 | TESTOSTERONE CYPIONATE 200MG/ML INJ 1ML | 202 | 25 | 40 |
| DEXTROAMPHETAMINE/AMPHETAM 30MG XR CAP-- | 2304 | 260 | 428 | AMOXICILLIN 250MG/5ML ORAL SUSP | 19995 | 1428 | 2892 |
| FLUTICASONE/SALMETEROL 250-50MCG INH DSK | 99 | 23 | 30 | ESCITALOPRAM 10MG (LEXAPRO) TAB | 2313 | 247 | 417 |
| LISINOPRIL 5MG ORAL TABLET | 2998 | 281 | 501 | CLONAZEPAM (KLONOPIN) PO 0.5MG TAB--PO 0 | 1780 | 235 | 365 |
| FLUCONAZOLE (DIFLUCAN) 150MG TAB--PO 150 | 142 | 17 | 27 | FOLIC ACID (FOLATE) 1MG TAB--PO 1MG TAB | 3696 | 371 | 641 |
| MECLIZINE HCL (ANTIVERT) 25 MG ORAL TAB- | 1928 | 178 | 319 | CETIRIZINE (ZYRTEC) 5MG/5ML PO SOLN--PO | 13314 | 1215 | 2190 |
| METOPROLOL SUCCINATE 50MG (TOPROL XL) | 3336 | 341 | 585 | AZITHROMYCIN (ZITHROMAX) 1GM PACK | 27 | 3 | 5 |
| CHORIONIC GONADOTROPIN(OVIDREL)250MCG SQ | 44 | 4 | 7 | ALLOPURINOL 100 MG ORAL TABLET--PO 100MG | 2943 | 332 | 548 |
| LANTUS INSULIN 100U/ML INJ | 857 | 108 | 171 | BUPROPION XL (WELLBUTRIN XL)150MG TAB--P | 2892 | 321 | 532 |
| OXYCODONE 5MG IR TAB ORAL--PO 5MG TAB | 11642 | 757 | 1609 | PROMETHAZINE HCL 25MG ORAL TABLET | 2496 | 180 | 363 |
| KETOCONAZOLE--TOP 2% SHAM | 7419 | 746 | 1289 | CELLUVISC 1% OPT DROP *OTC*--OPT AMP | 4119 | 311 | 612 |
| ONDANSETRON (ZOFRAN ODT) 4 MG TAB RAPDIS | 6318 | 260 | 723 | BENZOCAINE/MENTHOL (CEPACOL SORE THROAT) | 367 | 35 | 62 |
| FENTANYL (DURAGESIC) TDRM 50MCG/HR TDSY- | 79 | 18 | 24 | PANTOPRAZOLE SODIUM 40 MG ORAL TABLET DR | 2664 | 285 | 480 |
| METHOTREXATE NA(METHOTREXATE)2.5MG TAB | 1331 | 169 | 266 | AZITHROMYCIN(ZITHROMAX)200MG/5ML PO SUSP | 816 | 215 | 275 |
| CELECOXIB (CELEBREX) PO 200MG CAP--PO 20 | 3160 | 287 | 518 | WARFARIN SODIUM 2.5MG (GENERIC) TAB | 4327 | 469 | 786 |
| SILDENAFIL (VIAGRA) 50MG ORAL TABLET | 562 | 61 | 102 | MORPHINE (MS CONTIN) 30MG TBSR--PO 30MG | 370 | 80 | 107 |
| DEXTROAMPHETAMINE/AMPHETAM 10MG XR CAP-- | 1618 | 197 | 315 | ATORVASTATIN (LIPITOR) 80MG TAB | 5066 | 396 | 767 |
| OXYCODONE (OXYCONTIN) 40MG SR TAB | 434 | 86 | 118 | NAPROXEN (NAPROSYN) 500 MG ORAL TABLET | 18915 | 921 | 2306 |
| INSULIN ASPART (NOVOLOG) 100U/ML SUB-Q-- | 991 | 124 | 197 | NORETHINDRONE-E.ES-IRON 1MG-20(28) TAB | 2429 | 313 | 491 |
| FENTANYL (DURAGESIC) TDRM 75MCG/HR TDSY- | 42 | 11 | 14 | ALFUZOSIN HCL (UROXATRAL) 10MG ER TAB--P | 2194 | 250 | 411 |
| ATENOLOL 50 MG TAB | 2442 | 266 | 445 | GUAIFENESIN/CODEINE100-10MG/5ML ORAL SYR | 18573 | 1638 | 2998 |
| ASPIRIN (ASPIRIN EC) 81 MG ORAL TABLET-- | 42216 | 3111 | 6202 | NEEDLES INSULIN(SURE COMFORT)32GX0.25 IN | 7648 | 822 | 1382 |
| NORETHINDRONE (NOR-Q-D) 0.35 MG ORAL TAB | 6446 | 412 | 884 | CHOLECALCIFEROL(VITAMIN D3/D)400IU/ML PO | 7854 | 1676 | 2251 |
| OMEPRAZOLE (FIRST-OMEPRAZOLE) 2 MG/ML | 5520 | 656 | 1060 | LUBRICANT EYE DROPS (GENTEAL) *OTC* | 1663 | 174 | 296 |
| ELECTROLYTE MIXTURE (CO-LYTE GOLYTELY) | 458 | 490 | 524 | CLOTRIMAZOLE (MYCELEX) 1% CRM *OTC*--TOP | 1422 | 132 | 236 |
| ACETAMINOPHEN(MAPAP)160MG/5MLORAL ELIXIR | 40617 | 1856 | 4830 | PROGESTERONE IN OIL 50MG/ML VIAL*NF* | 758 | 78 | 133 |
| CHLORHEXIDINE GLUCONATE 0.12 % MOUTHWASH | 84234 | 6076 | 12244 | LORAZEPAM (ATIVAN) PO 1MG TAB--PO 1MG TA | 1100 | 153 | 234 |
| PENICILLIN V K 500MG ORAL TABLET | 878 | 97 | 161 | OLOPATADINE HCL (PATANOL) 0.1 % OPH DROP | 107 | 14 | 21 |
| ATENOLOL 25 MG TAB | 2083 | 237 | 389 | MORPHINE (MS CONTIN) 15MG TBSR--PO 15MG | 584 | 103 | 146 |
| HYDROXYZINE HCL (ATARAX) 10MG ORAL TAB | 2549 | 314 | 501 | DIAZEPAM (VALIUM) 5MG PO TAB--PO 5MG TAB | 4269 | 351 | 664 |
| POLYMYXIN B TRIMETHOPRIM OPTH SOLN--OPT | 514 | 41 | 79 | METOPROLOL SUCCINATE 25MG (TOPROL XL) | 3169 | 305 | 537 |
| NAPROXEN (NAPROSYN) 375 MG ORAL TABLET | 1547 | 162 | 276 | LORATADINE/P-EPHED (CLARITIN-D) 12HR--PO | 1403 | 161 | 263 |

## C.  RECOMMENDATIONS

This study has solidified two big ideas in inventory management; grouping is a very good and easy way to reduce costs and a continuous review system is the most accurate and efficient inventory system. NMCSD should consider adopting a group ordering strategy that would reduce the number of orders made per year and thus reduce total cost and begin looking into costs associated with implementing a continuous review system.

## D. AREAS FOR FURTHER RESEARCH

Logistical areas of research that can benefit Navy Pharmacy and inventory management are:

- Re-visit the order cost assumptions providing more in-depth analysis of the order cost and increasing their accuracy

- Cost-benefit analysis looking specifically at a continuous review system

- Investigate pooling inventory regionally, nationally or at one location to cover hospitals and clinics in a local catchment area.

- Perform experimentation to better split the S and $S^*$ cost parameters

# LIST OF REFERENCES

Aksoy, Y., & Erenguc, S. S. (1988). Multi-Item Inventory Models with Co-ordinated Replenishments: A Survey. *International Journal of Operations & Production Management*, *8*(1), 63–73.

Ali, A. K. (2011). Inventory Management in Pharmacy Practice: A Review of Literature. *Archives of Pharmacy Practice, 2*(4), 151–156.

American Society of Health-System Pharmacists. (2008). ASHP Guidelines on Medicaton Cost Management Strategies for Hospitals and Health Systems. Retrieved Sep 20, 2016, from https://www.ashp.org/DocLibrary/BestPractices/MgmtGdlCostManag.aspx

Bouldin, A. S., Holmes, R. E., & Garner, D. D. (2011). Purchasing and Managing Inventory. In M. A. Burns, & A. P. Vaillancourt, *Pharmacy Management, Leadership, Marketing and Finance* (pp. 149–162). Sudbury, MA: Jones and Bartlett Publishers.

Boyle, A. M. (2013, August). New Procedures for Navy Pharmacy Save more than $35 million, Improve Care. *U.S. Medicine*. Retrieved Sep 25, 2016, from http://www.usmedicine.com/agencies/department-of-defense-dod/new-procedures-for-navy-pharmacy-save-more-than-35-million-improve-care/

Chopra, S., & Meindl, P. (2013). *Supply Chain Management Strategy, Planning and Operation.* Upper Saddle River, NJ: Prentice Hall Publishing.

Congressional Budget Office. (2014, January). *Approaches to Reducing Federal Spending on Military Health Care*. Retrieved September 15, 2016, from https://www.cbo.gov/sites/default/files/113th- congress-2013-2014/reports/44993-MilitaryHealthcare.pdf

Defense Travel Management Office. (2016). Retrieved October 15, 2016, from BAH Calculator: http://www.defensetravel.dod.mil/pdcgi/bah/bahsrch.cgi

Dennis, B. (2015, November 3). Nearly 60 percent of Americans —the highest ever— are taking prescription drugs. *Washington Post.* Retrieved from http://washingtonpost.com

Devani, M., Gupta, Ak., & Nigah, R. (2010). ABC and VED Analysis of the Pharmacy Store of a Tertiary Care Teaching, Research and Referral Healthcare Institute of India. *Journal of Young Pharmacists*, *2* (2), 201–205.

San Diego Locality Area-General Schedule Localities. (2016). Retrieved October 15, 2016, from https://www.federalpay.org/gs/locality/san-diego

Government Accountability Office. (2008, April 4). *DOD program: Continued efforts needed to reduce growth in spending at retail pharmacies* (GAO-08-327). Washington, DC: Author. Retrieved from http://www.gao.gov/products/GAO-08-327

Ingersol, K. P. (2015, June 1). *Inventory Management for the Pharmacy Technician.* Retrieved November 10, 2016, from https://s3.amazonaws.com/EliteCME_WebSite_2013/f/pdf/RPTFL04IMI14.pdf

Inventory management: How to improve your pharmacy's bottom Line. (2013, May 14). *Elements.* Retrieved from https://www.pbahealth.com/inventory-management-how-to-improve-your-pharmacys-bottom-line/

Krajewski, L., & Ritzman, L. (1996). *Operations Management Strategy and Analysis* (4th ed.). Reading, MA: Addison-Wesley Publishing Company.

Lavinsky, D. (2014, Jan 20). Pareto Principle: How to use it to Dramatically Grow your Business. *Forbes*. Retrieved Sep. 25, 2016, from http://www.forbes.com/

Lipton, E., & Abrams, R. (2016, Sep 16). EpiPen Maker Lobbies to Shift High Costs To Others. *New York Times.* Retrieved Oct 7, 2016, from http://www.nytimes.com

Military pay chart for 2016 (2016). Retrieved October 16, 2016, from http://www.militaryrates.com/military-pay-charts-e1_e5_2016

National Community Pharmacists Association. (2008). Managing Pharmacy Inventory. Retrieved Oct 10, 2016, from http://bccpharmacytech.weebly.com/uploads/7/5/0/4/7504847/ownership- managinginventory.pdf

Pantumsinchai, P. (1992). A Comparison of Three Joint Ordering Inventory Policies. *Decision Sciences*, *23*(1), 111–127.

Caduet. (2016). Retrieved Oct 7, 2016, from http://www.pfizer.com/products/product-detail/caduet

Science Applications International Corporations. (1996, July 29). Pharmacy Reference Manual CHCS (SAIC/CHCS Doc. TC-4.5-0703). San Diego, CA: Author. Retrieved from https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=1&ved=0ahUKEwiZnNWH1bfQAhUCQiYKHfQECC0QFggdMAA&url=http%3A%2F%2Fwww.navyehr.org%2Fhelp-top-menu%2Foverview-resources-materials%2Fdocument-repository%2Fdoc_download%2F118-reference-manual&usg=AFQjCNFZuVrwvnw4E2H_gSrfIulInxOHHg

Seftil, C. (n.d.). *101 Years Old—A Re-Look at EOQ*. Retrieved Oct 15, 2016, from http://www.psq.co.za/news25.htm

Sloan, L. (2015, Nov 4). 4 Ways to Reduce Your Procurement Costs Overnight. *SciQuest*. Retrieved Oct 7, 2016, from https://www.sciquest.com/blog/4-ways-reduce- your-procurement-costs-overnight

Willard, G. (2012, Apr 8). Perpetual Inventory Systems: A pharmacy Perspective. *Ezine Articles*. Retrieved Sep 28, 2016, from http://ezinearticles.com/?Perpetual-Inventory-Systems---A-Pharmacy-Perspective&id=6989375

World Health Organization. (2012). *MDS-3 Managing Access to Medicines and Health Technologies* (3rd Ed.). Arlington, VA: Management Sciences for Health.

THIS PAGE INTENTIONALLY LEFT BLANK

# INITIAL DISTRIBUTION LIST

1.      Defense Technical Information Center
        Ft. Belvoir, Virginia

2.      Dudley Knox Library
        Naval Postgraduate School
        Monterey, California